氩氦刀联合中药治疗Ⅲb期～Ⅳ期非小细胞肺癌的临床研究
|
摘要
目的：本课题采用回顾性的研究方法,通过对126例经过氩氦刀联合中药治疗的晚期(Ⅲb期～Ⅳ期)非小细胞肺癌患者的随访资料进行统计分析,总结其规律,分析肺癌局部微观辨证的特点及氩氦刀冷冻治疗的中医机理,为氩氦刀联合中药临床应用提供一定的临床依据及指导,评估“氩氦刀+中药”这一绿色治疗模式对晚期非小细胞肺癌患者的临床治疗价值,对其治疗时机进行优化,努力为晚期肺癌患者提供更加成熟的治疗方案。
方法：采用回顾性的研究方法总结2003年9月至2013年5月在东方医院肿瘤科住院行氩氦刀冷冻联合中药治疗的Ⅲb期～Ⅳ期原发性非小细胞肺癌患者126例,分析其肺部肿瘤特点及氩氦刀冷冻治疗影像资料,研究肺癌局部微观辨证的特点及氩氦刀冷冻治疗的中医机理,并对患者生存期进行分析；另设健康对照30例,对其外周血免疫指标进行对比研究,以对这一方案治疗晚期非小细胞肺癌患者的临床价值进行评估。
研究结果：
[1]患者耐受情况126例Ⅲb期～Ⅳ期NSCLC患者顺利完成手术,并接受了较长时间的中医药治疗,无术中死亡病例,术中术后并发症轻微、恢复快。
[2]生存期、生存率分析：
①总体情况：126例患者治疗后中位生存期12个月,总中位生存期18个月。
②生存率情况：126例患者冷冻治疗后随访6月、12月、18月、24月、36月生存率依次是69.8%(88/126)、42.9%(51/119)、26.8%(30/112)、12.7%(14/110)、5.6%(6/108)；自确诊起6月、12月、18月、24月、36月总生存率依次是91.3%、71.3%、48.3%、31.6%、13.5%。
③从年龄角度来看：年龄<65岁患者术后中位生存期9个月、总中位生存期15个月；年龄≥65岁患者术后中位生存期14个月、总中位生存期22个月,术后中位生存两者存在显著性差异(p=0.013)。老龄患者更倾向于首选微创、低毒的治疗方案,看似保守的选择反而使其生存期获益。
④从病理角度来看：80例腺癌患者术后中位生存期11个月,总中位生存期17个月；30例鳞癌患者术后中位生存期8个月,总中位生存期19个月；两组无统计学差异(术后p=0.213,总p=0.838)。
⑤从TNM分期角度来看：40例Ⅲb期患者术后中位生存期14个月,总中位生存期25个月；86例Ⅳ期患者术后中位生存期8个月,总中位生存期17个月。Ⅲb期患者确实较Ⅳ期患者有更好的生存期,两者存在显著性差异(术后p=0.029；总p=0.045)。
⑥从原发肺癌病灶位置来看：56例中央型肺癌患者术后中位生存期9个月,总体中位生存期17个月；70例周围型肺癌患者术后中位生存期12个月,总体中位生存期20个月。虽然两者差异并不显著(术后p=0.238；总p=0.367),但从数据上来讲,晚期周围型肺癌生存期表现较中央型要好一些。
⑦从冷冻靶病灶大小角度来看：13例≤3cm者术后生存期23个月,总生存期29个月；53例3-5cm者术后生存期14个月,总生存期22个月；42例5-8cm者术后生存期7个月,总生存期15个月；18例≥8cm者术后生存期7个月,总生存期14个月。对于负荷小于5cm的肺癌患者来讲,其治疗后生存期、总生存期均明显优于大于5cm肿瘤负荷患者,存在显著差异(p<0.05)。
⑨从治疗时机的角度来看：46例患者确诊后确诊后1个月内入住我院行氩氦刀联合中药治疗的患者,术后中位生存期13个月,18例2-3个月治疗者术后中位生存期12个月,9例4-6个月者治疗后中位生存期10个月,53例>6个月者术后中位生存期9个月(P>0.05)。
[3]冷冻比率分析
94例患者可以对术中瘤灶的冷冻比率评价。8例瘤灶≤3cm的患者平均冷冻比率98.5%,37例瘤灶3-5cm的患者平均冷冻比率85.0%,33例瘤灶5-8cm的患者平均冷冻比率73.7%,16例瘤灶≥8cm的患者平均冷冻比率49.6%。病灶越小,冷冻比率越高,冰球完全覆盖肿瘤达到局部病灶根治性冷冻的可能性越大。
94例患者中,中央型肺癌55例,平均冷冻比率73.2%；周围型肺癌39例,平均冷冻比率84.8%。11例心脏大血管受侵患者平均冷冻比率64.8%：13例患者大面积肺不张,平均冷冻比率69.1%。周围型肺癌较中央型肺癌冷冻比率更高。
20例冷冻比率≤50%的患者术后中位生存期8个月；23例冷冻比率在50%-80%的患者术后中位生存期6个月；28例冷冻比率80%-100%的患者术后中位生存期14个月；23例冷冻比率≥100%的患者术后中位生存期18个月。冷冻比率越高患者生存获益越明显。
[4]氩氦刀时机的选择
无论是初治时还是疾病进展以后选择氩氦刀冷冻治疗,都能使患者治疗后生存期获益,但患者术后生存曲线提示,晚期肺癌患者越是早期采用氨氦刀联合中药治疗,其术后生存获益可能越明显。
[5]晚期肺癌患者免疫状态
126例患者中38例在冷冻联合中药治疗前检测了外周血T细胞亚群、NK细胞,与30例健康患者外周血T细胞及NK细胞水平比较显示：晚期肺癌患者外周血CD4+比例降低(p=0.003),而CD8+水平升高(p=0.010),统计学存在显著差异。表明晚期肺癌患者免疫功能相对较差,或者处于免疫抑制的状态。提示临床可能需要增强免疫治疗。而21例患者冷冻治疗前后外周血免疫指标对比无明显差异,提示氩氦刀冷冻治疗短期内并未改变患者的免疫功能。
[6]肺癌的局部微观辨证
综合文献及借助于现代影像技术,肺癌局部病变“红”“肿”“热”特征明显,加之其无限增生、侵袭性、转移性无不揭示着其异常的阳动之性,其局部肿瘤处于明显的阳热证状态,热毒亢盛。
[7]氩氦刀冷冻治疗肺癌的中医机理
氩氦刀治疗肺癌法以“热者寒之”,使阴寒之法直达热邪之所,从而使有形之热邪最终得以消散于无形。氩氦刀冷冻的治疗肺癌是辨证治疗。
结论：
[1]氩氦刀联合中药治疗NSCLC安全有效,可以使IIIb-IV期患者生存获益。
[2]“氩氦刀+中药”模式是基于短期快速减轻肿瘤负荷、长期绿色低毒体质调理的可持续的治疗思路,可以作为IIIb期～IV期肺癌患者治疗的主要方案。
[3]肺癌局部微观辨证是阳热毒邪,氩氦刀形成的冰球性“寒”；法以“热者寒之”,采用氩氦刀冷冻治疗肺癌是对“证”治疗,是辨证治疗,切实可行。
[4]晚期肺癌患者免疫功能降低,临床治疗应当增强免疫治疗。
[5]本课题提出了冷冻比率的计算方法,研究显示提高冷冻比率有利于使患者临床生存获益。
Objective:A retrospective clinical study was carried out on126advanced (Ⅲb-IV) non-small cell lung cancer (NSCLC) patients who accepted the therapy of cryosurgery combined with TCM, to analyze local microdialectics characteristic of lung cancer and TCM mechanism of cryosurgery therapy, which can provide clinical evidence and guidance, furthermore, to evaluate the clinical value of the "Cryosurgery-TCM" green therapy model, optimize cryosurgery and provid a mor perfect therapy for advanced lung cancer patients.
Methods:126advanced NSCLC patients who accepted cryosurgery-TCM therapy during September2003to May2013in oncology department, Dongfang hospital, were enrolled in this study. The clinical data, including lung cancer characteristic, cryosurgery related image data, local microdialectics characteristic of lung cancer and TCM mechanism of cryosurgery were collected in order to analyze survival time of different patients. Meanwhile,30relative normal control cases were also enrolled. Peripheral immune status was compared between the two groups. Then clinical value of the cryosurgery-TCM therapy model was evaluated on advanced NSCLC patients.
Results:
[1] Patients' endurance summary
All the126NSCLC patients underwent cryosurgery successfully and received TCM therapy for long time. During ablation no death occurred. The complications during and after ablation were mild and revovered fast.
[2] Survival rate analysis
①General description:
For the total126patients, the median survival time was12months and the overall survival time was18months.
②Survival rate description:
The survival rates were69.8%(88/126),42.9%(51/119),26.8%(30/112),12.7%(14/110) and5.6%(6/108) at the time of the6th,12th,18th,24th and36th months after cryosurgery, respectively. When calculating from the date of NSCLC diagnosis, the survival rates were91.3%,71.3%,48.3%,31.6%and13.5%correspondingly.
③Survival analysis based on incident age:
Younger patients (<65years old) achieved15months overall survival time and9months after-cryosurgery survival time, while older patients (≥65years) achieved22months overall survival time with14months after-cryosurgery survival time. Significant difference was observed of after-cryosurgery survival time (p=0.013). The elder tended to accept conservative choice of minimal invasive and less toxic therapy, Which gained a better survival benefits.
④Survival analysis based on pathology:
80adenocarcinoma lung cancer patients, achieved17months overall survival time and11months median survival time. While30squamous cell carcinoma lung cancer patients, achieved19months overall survival time with8months median survival time (after-cryosurgery p=0.213,overall p=0.838). There were on significant differences between the two pathologic types.
⑤Survival time based on TNM stages:
For the40Ⅲb phase patients, they got25months survival time and14months median survival time. Eighty-six IV stage patients gained17months overall survival time and8months median survival time. Ⅲb stage patients had a longer survival time (after-cryosurgery p=0.029, overall p=0.045)
⑥Survival time based on primary lung cancer locations:
56central lung cancer patients had17months overall survival time and9months median survival time, meanwhile,70peripheral lung cancer patients had20overall survival time and12months median survival time (after-cryosurgery p=0.238, overall p=0.367).Advanced peripheral lung cancer patients had more advantages when accepted this therapy model.
⑦Survival time based on target cryo-lesions size:
There were13、53、42and18patients whose target cryo-lesions size were≤3cm,3-5cm、5～8cm and≥8cm, respectively. Their overall and median survival times were29、22、15、14months and23、14、7、7months correspondingly. The more tumor load, the shorter survival time was.(p<0.05)
⑧Survival time based on therapy time points:
According to the time points, there were46,18,9and53patients suffering from lung cancer for1,2～3,4～6and>6months when patients accepted cryosurgery, respectively. Their median survival times were13,12,10and9months correspondingly(P>0.05).[3]Lesion cryoablation coverage rate analysis:
Lesion cryoablation coverage rate was evaluated in94patients. There were8,37,33and16patients with≤3cm,3～5cm,5～8cm and≥8cm lung cancer cryo-lesions. Their mean cryoablation coverage rates were98.5%,85.0%,73.7%and49.6%, respectively. The higher cryo-coverage rate can be found in small size lesions.
In the94patients,55patients were central lung cancer and39patients were peripheral lung cancer. Their mean cryo-coverage rates were73.2%and84.8%, respectively. The mean cryo-coverage rate in11patients with heart vascular invasion was64.8%which that in13patients with large areas of atelectasis was69.1%. Higher cryo-coverage rate can be seen in peripheral lung cancer patients than that in central lung cancer patients.
The association between cryo-coverage rate and survival time was analyzed. There were20,23,28and23patients with≤50%,50%-80%,80%-100%and≥100%cryo-coverage rate. Their median survival times were8,6,14and18months. Patients who got higher cryo-coverage rate gained a longer survival time.
[4]Cryosurgery time analysis:
The patients who received cryosurgery can have a longer survival time in the period of initial treatment or disease progression. However, advanced lung cancer patients who accepted cryosurgery-TCM earlier would get more benifits.
[5]Immune status analysis:
Peripheral blood was got from38lung cancer patients and30relative mormal control cases. The amounts of T cells, NK cells were tested. CD4+cell ratio in peripheral blood decreased (p=0.003), while CD8+cells ratio increased significantly (p=0.010). Advanced lung cancer patients had a relative bad immune function or were in immunosuppression status. Which means the cryosurgery didn't change immune function in the short time.
[6] Local micro dialectics characteristic analysis:
According to documents and morden image technology, the features, such as "red","swollen","hot" and "pain", were obvious. Meantime, the lung cancer had "Yang" features, such as unlimited growth, invasion and metastases, which showed the local tumor belonged to toxic heat syndrome.[7] TCM mechanism of cryosurgery application for lung cancer:
A principle for lung cancer cryosurgery application is "treating hot syndrome with cold natured drugs", which is a classic TCM theory. TCM theory indicates that the solid tumor of a "hot" feature can disappear if the "cold" can reach. The cryosurgery for lung cancer is a differential treatment.
Conclusion:
[1] It is safe and effective for advanced NSCLC patients (stage Ⅲb-Ⅳ) who accept cryosurgery plus TCM therapy.
[2] Cryosurgery plus TCM therapy model is a new and promisingstrategy for advanced NSCLC patients (stage IIIb-IV), and it can decrease tumor load rapidly and sequential low toxic green TCM therapy providing the possibility for patients" physique adjustment.
[3] It is feasible to treat lung cancer with cryosurgery therapy based on local lung cancer micro dialectics characteristic. The ice ball forming during cryosurgery therapy is "cold", and it matches with "hot" of local lung cancer. It can be clarified by TCM principle "treating hot syndrome with cold natured drugs".
[4] The immune function should be enhanced for advanced lung cancer during our clinical practice.[5] The method of lesion cryo-coverage rate was established, higher cryo-coverage rate of lung cancer is useful for better survival time.
方法：采用回顾性的研究方法总结2003年9月至2013年5月在东方医院肿瘤科住院行氩氦刀冷冻联合中药治疗的Ⅲb期～Ⅳ期原发性非小细胞肺癌患者126例,分析其肺部肿瘤特点及氩氦刀冷冻治疗影像资料,研究肺癌局部微观辨证的特点及氩氦刀冷冻治疗的中医机理,并对患者生存期进行分析；另设健康对照30例,对其外周血免疫指标进行对比研究,以对这一方案治疗晚期非小细胞肺癌患者的临床价值进行评估。
研究结果：
[1]患者耐受情况126例Ⅲb期～Ⅳ期NSCLC患者顺利完成手术,并接受了较长时间的中医药治疗,无术中死亡病例,术中术后并发症轻微、恢复快。
[2]生存期、生存率分析：
①总体情况：126例患者治疗后中位生存期12个月,总中位生存期18个月。
②生存率情况：126例患者冷冻治疗后随访6月、12月、18月、24月、36月生存率依次是69.8%(88/126)、42.9%(51/119)、26.8%(30/112)、12.7%(14/110)、5.6%(6/108)；自确诊起6月、12月、18月、24月、36月总生存率依次是91.3%、71.3%、48.3%、31.6%、13.5%。
③从年龄角度来看：年龄<65岁患者术后中位生存期9个月、总中位生存期15个月；年龄≥65岁患者术后中位生存期14个月、总中位生存期22个月,术后中位生存两者存在显著性差异(p=0.013)。老龄患者更倾向于首选微创、低毒的治疗方案,看似保守的选择反而使其生存期获益。
④从病理角度来看：80例腺癌患者术后中位生存期11个月,总中位生存期17个月；30例鳞癌患者术后中位生存期8个月,总中位生存期19个月；两组无统计学差异(术后p=0.213,总p=0.838)。
⑤从TNM分期角度来看：40例Ⅲb期患者术后中位生存期14个月,总中位生存期25个月；86例Ⅳ期患者术后中位生存期8个月,总中位生存期17个月。Ⅲb期患者确实较Ⅳ期患者有更好的生存期,两者存在显著性差异(术后p=0.029；总p=0.045)。
⑥从原发肺癌病灶位置来看：56例中央型肺癌患者术后中位生存期9个月,总体中位生存期17个月；70例周围型肺癌患者术后中位生存期12个月,总体中位生存期20个月。虽然两者差异并不显著(术后p=0.238；总p=0.367),但从数据上来讲,晚期周围型肺癌生存期表现较中央型要好一些。
⑦从冷冻靶病灶大小角度来看：13例≤3cm者术后生存期23个月,总生存期29个月；53例3-5cm者术后生存期14个月,总生存期22个月；42例5-8cm者术后生存期7个月,总生存期15个月；18例≥8cm者术后生存期7个月,总生存期14个月。对于负荷小于5cm的肺癌患者来讲,其治疗后生存期、总生存期均明显优于大于5cm肿瘤负荷患者,存在显著差异(p<0.05)。
⑨从治疗时机的角度来看：46例患者确诊后确诊后1个月内入住我院行氩氦刀联合中药治疗的患者,术后中位生存期13个月,18例2-3个月治疗者术后中位生存期12个月,9例4-6个月者治疗后中位生存期10个月,53例>6个月者术后中位生存期9个月(P>0.05)。
[3]冷冻比率分析
94例患者可以对术中瘤灶的冷冻比率评价。8例瘤灶≤3cm的患者平均冷冻比率98.5%,37例瘤灶3-5cm的患者平均冷冻比率85.0%,33例瘤灶5-8cm的患者平均冷冻比率73.7%,16例瘤灶≥8cm的患者平均冷冻比率49.6%。病灶越小,冷冻比率越高,冰球完全覆盖肿瘤达到局部病灶根治性冷冻的可能性越大。
94例患者中,中央型肺癌55例,平均冷冻比率73.2%；周围型肺癌39例,平均冷冻比率84.8%。11例心脏大血管受侵患者平均冷冻比率64.8%：13例患者大面积肺不张,平均冷冻比率69.1%。周围型肺癌较中央型肺癌冷冻比率更高。
20例冷冻比率≤50%的患者术后中位生存期8个月；23例冷冻比率在50%-80%的患者术后中位生存期6个月；28例冷冻比率80%-100%的患者术后中位生存期14个月；23例冷冻比率≥100%的患者术后中位生存期18个月。冷冻比率越高患者生存获益越明显。
[4]氩氦刀时机的选择
无论是初治时还是疾病进展以后选择氩氦刀冷冻治疗,都能使患者治疗后生存期获益,但患者术后生存曲线提示,晚期肺癌患者越是早期采用氨氦刀联合中药治疗,其术后生存获益可能越明显。
[5]晚期肺癌患者免疫状态
126例患者中38例在冷冻联合中药治疗前检测了外周血T细胞亚群、NK细胞,与30例健康患者外周血T细胞及NK细胞水平比较显示：晚期肺癌患者外周血CD4+比例降低(p=0.003),而CD8+水平升高(p=0.010),统计学存在显著差异。表明晚期肺癌患者免疫功能相对较差,或者处于免疫抑制的状态。提示临床可能需要增强免疫治疗。而21例患者冷冻治疗前后外周血免疫指标对比无明显差异,提示氩氦刀冷冻治疗短期内并未改变患者的免疫功能。
[6]肺癌的局部微观辨证
综合文献及借助于现代影像技术,肺癌局部病变“红”“肿”“热”特征明显,加之其无限增生、侵袭性、转移性无不揭示着其异常的阳动之性,其局部肿瘤处于明显的阳热证状态,热毒亢盛。
[7]氩氦刀冷冻治疗肺癌的中医机理
氩氦刀治疗肺癌法以“热者寒之”,使阴寒之法直达热邪之所,从而使有形之热邪最终得以消散于无形。氩氦刀冷冻的治疗肺癌是辨证治疗。
结论：
[1]氩氦刀联合中药治疗NSCLC安全有效,可以使IIIb-IV期患者生存获益。
[2]“氩氦刀+中药”模式是基于短期快速减轻肿瘤负荷、长期绿色低毒体质调理的可持续的治疗思路,可以作为IIIb期～IV期肺癌患者治疗的主要方案。
[3]肺癌局部微观辨证是阳热毒邪,氩氦刀形成的冰球性“寒”；法以“热者寒之”,采用氩氦刀冷冻治疗肺癌是对“证”治疗,是辨证治疗,切实可行。
[4]晚期肺癌患者免疫功能降低,临床治疗应当增强免疫治疗。
[5]本课题提出了冷冻比率的计算方法,研究显示提高冷冻比率有利于使患者临床生存获益。
Objective:A retrospective clinical study was carried out on126advanced (Ⅲb-IV) non-small cell lung cancer (NSCLC) patients who accepted the therapy of cryosurgery combined with TCM, to analyze local microdialectics characteristic of lung cancer and TCM mechanism of cryosurgery therapy, which can provide clinical evidence and guidance, furthermore, to evaluate the clinical value of the "Cryosurgery-TCM" green therapy model, optimize cryosurgery and provid a mor perfect therapy for advanced lung cancer patients.
Methods:126advanced NSCLC patients who accepted cryosurgery-TCM therapy during September2003to May2013in oncology department, Dongfang hospital, were enrolled in this study. The clinical data, including lung cancer characteristic, cryosurgery related image data, local microdialectics characteristic of lung cancer and TCM mechanism of cryosurgery were collected in order to analyze survival time of different patients. Meanwhile,30relative normal control cases were also enrolled. Peripheral immune status was compared between the two groups. Then clinical value of the cryosurgery-TCM therapy model was evaluated on advanced NSCLC patients.
Results:
[1] Patients' endurance summary
All the126NSCLC patients underwent cryosurgery successfully and received TCM therapy for long time. During ablation no death occurred. The complications during and after ablation were mild and revovered fast.
[2] Survival rate analysis
①General description:
For the total126patients, the median survival time was12months and the overall survival time was18months.
②Survival rate description:
The survival rates were69.8%(88/126),42.9%(51/119),26.8%(30/112),12.7%(14/110) and5.6%(6/108) at the time of the6th,12th,18th,24th and36th months after cryosurgery, respectively. When calculating from the date of NSCLC diagnosis, the survival rates were91.3%,71.3%,48.3%,31.6%and13.5%correspondingly.
③Survival analysis based on incident age:
Younger patients (<65years old) achieved15months overall survival time and9months after-cryosurgery survival time, while older patients (≥65years) achieved22months overall survival time with14months after-cryosurgery survival time. Significant difference was observed of after-cryosurgery survival time (p=0.013). The elder tended to accept conservative choice of minimal invasive and less toxic therapy, Which gained a better survival benefits.
④Survival analysis based on pathology:
80adenocarcinoma lung cancer patients, achieved17months overall survival time and11months median survival time. While30squamous cell carcinoma lung cancer patients, achieved19months overall survival time with8months median survival time (after-cryosurgery p=0.213,overall p=0.838). There were on significant differences between the two pathologic types.
⑤Survival time based on TNM stages:
For the40Ⅲb phase patients, they got25months survival time and14months median survival time. Eighty-six IV stage patients gained17months overall survival time and8months median survival time. Ⅲb stage patients had a longer survival time (after-cryosurgery p=0.029, overall p=0.045)
⑥Survival time based on primary lung cancer locations:
56central lung cancer patients had17months overall survival time and9months median survival time, meanwhile,70peripheral lung cancer patients had20overall survival time and12months median survival time (after-cryosurgery p=0.238, overall p=0.367).Advanced peripheral lung cancer patients had more advantages when accepted this therapy model.
⑦Survival time based on target cryo-lesions size:
There were13、53、42and18patients whose target cryo-lesions size were≤3cm,3-5cm、5～8cm and≥8cm, respectively. Their overall and median survival times were29、22、15、14months and23、14、7、7months correspondingly. The more tumor load, the shorter survival time was.(p<0.05)
⑧Survival time based on therapy time points:
According to the time points, there were46,18,9and53patients suffering from lung cancer for1,2～3,4～6and>6months when patients accepted cryosurgery, respectively. Their median survival times were13,12,10and9months correspondingly(P>0.05).[3]Lesion cryoablation coverage rate analysis:
Lesion cryoablation coverage rate was evaluated in94patients. There were8,37,33and16patients with≤3cm,3～5cm,5～8cm and≥8cm lung cancer cryo-lesions. Their mean cryoablation coverage rates were98.5%,85.0%,73.7%and49.6%, respectively. The higher cryo-coverage rate can be found in small size lesions.
In the94patients,55patients were central lung cancer and39patients were peripheral lung cancer. Their mean cryo-coverage rates were73.2%and84.8%, respectively. The mean cryo-coverage rate in11patients with heart vascular invasion was64.8%which that in13patients with large areas of atelectasis was69.1%. Higher cryo-coverage rate can be seen in peripheral lung cancer patients than that in central lung cancer patients.
The association between cryo-coverage rate and survival time was analyzed. There were20,23,28and23patients with≤50%,50%-80%,80%-100%and≥100%cryo-coverage rate. Their median survival times were8,6,14and18months. Patients who got higher cryo-coverage rate gained a longer survival time.
[4]Cryosurgery time analysis:
The patients who received cryosurgery can have a longer survival time in the period of initial treatment or disease progression. However, advanced lung cancer patients who accepted cryosurgery-TCM earlier would get more benifits.
[5]Immune status analysis:
Peripheral blood was got from38lung cancer patients and30relative mormal control cases. The amounts of T cells, NK cells were tested. CD4+cell ratio in peripheral blood decreased (p=0.003), while CD8+cells ratio increased significantly (p=0.010). Advanced lung cancer patients had a relative bad immune function or were in immunosuppression status. Which means the cryosurgery didn't change immune function in the short time.
[6] Local micro dialectics characteristic analysis:
According to documents and morden image technology, the features, such as "red","swollen","hot" and "pain", were obvious. Meantime, the lung cancer had "Yang" features, such as unlimited growth, invasion and metastases, which showed the local tumor belonged to toxic heat syndrome.[7] TCM mechanism of cryosurgery application for lung cancer:
A principle for lung cancer cryosurgery application is "treating hot syndrome with cold natured drugs", which is a classic TCM theory. TCM theory indicates that the solid tumor of a "hot" feature can disappear if the "cold" can reach. The cryosurgery for lung cancer is a differential treatment.
Conclusion:
[1] It is safe and effective for advanced NSCLC patients (stage Ⅲb-Ⅳ) who accept cryosurgery plus TCM therapy.
[2] Cryosurgery plus TCM therapy model is a new and promisingstrategy for advanced NSCLC patients (stage IIIb-IV), and it can decrease tumor load rapidly and sequential low toxic green TCM therapy providing the possibility for patients" physique adjustment.
[3] It is feasible to treat lung cancer with cryosurgery therapy based on local lung cancer micro dialectics characteristic. The ice ball forming during cryosurgery therapy is "cold", and it matches with "hot" of local lung cancer. It can be clarified by TCM principle "treating hot syndrome with cold natured drugs".
[4] The immune function should be enhanced for advanced lung cancer during our clinical practice.[5] The method of lesion cryo-coverage rate was established, higher cryo-coverage rate of lung cancer is useful for better survival time.
引文
1. Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non-small cell Lung Cancer[J]. N Engl J Med,2002,346:92-98.
2. 赫捷,陈万青.2012中国肿瘤登记年报[M].北京：军事医学科学出版社,2012,10.
3. 孙桂芝主编.实用中医肿瘤学[M].北京：中国中医药出版社,2010：151.
4. Waun Ki Hong, MD:Anne S. Tsao, MD. Lung Carcinoma. The Merck Manual for Health Care Professionals, Merck & Co. Inc. http://www.merckmanuals.com/2012.4.22.
5. 朱明章,吴万根.中医专方联合化疗治疗非小细胞肺癌疗效及组方研究.广州中医药大学博士学位论文,2013,5.
7. 赵炜.李佩文治疗肺癌的经验[J].北京中医,2002,21(6)：329.
8. 郁仁存.中医肿瘤学(上册).北京：北京科学出版社,1983,275.
9. 周岱翰.肿瘤治验集要[M].广州：广东省教育出版社,1997.36.
10.刘嘉湘.肺癌证治.中医杂志,1986,(3)：4-7.
11.周晓园,陶凯.顾振东治疗肿瘤的经验[J].中医杂志,1999,40(7)：395.
12.魏华.晚期肺癌的中医药治疗.湖北中医杂志,2000,2(：8)12-13.
13.姜敏,胡凯文.肺癌患者氩氦刀冷冻术后中医证候特点研究.北京中医药大学七年制学位论文,2004.5.
14.朴炳奎.原发性支气管肺癌中西医结合治疗方案[J].中国肿瘤,1995,4(5)：4-6.
15.刘嘉湘,施志明,徐振晔,等.滋阴生津益气温阳法治疗晚期原发性肺腺癌的临床观察[J].中医杂志,1995,36(3)：155-158.
16.孙建立.刘嘉湘教授治疗原发性非小细胞肺癌辨证和用药规律分析[J],第三届国际中医、中西医结合肿瘤学术交流大会暨第十二届全国中西医结合肿瘤学术大会论文汇编[C].2010,230-235.
17.王笑民,郁仁存.晚期非小细胞肺癌患者气虚血瘀证的研究.中国中西医结合杂志,1994,14：(12)：724.
18.李忠,陈信义,姜苗.肿癌中医临床研究进展与用药思路[J].中国医药学报,2004,19(3)：176.
19.郑翠娥.顾振东治疗肺癌经验[J].山东中医杂志,1996,15(5)：225-226.
20.左明焕,王芬,孙韬.晚期肺癌的中医证候研究[J].北京中医药大学学报,2003,10(4)：7-9.
21.侯丽,姜苗,陈信义,等.晚期非小细胞肺癌中医证候特征回顾性临床研究田.中国中医药信息杂志,2007,14(4)：19-21.
22.张月,张培彤,赵冰,等.基于聚类分析的肺癌中医证候分类及诊断的研究[J].北京中医药人学学报,2009,32(2)：132-135.
23.王芬,周而复,陈文强,等.中晚期肺癌中医证候与患者生活质量关系的分析[J].中国中医药信息杂志,2007,14(2)：21-22.
24. 陈涛,陈茂华.原发性支气管肺癌临床证型的文献统计分析[J].时珍国医国药,2006,17(5)：854-855.
25.游捷,李泰峰.303例老年原发性支气管肺癌中医证候分型[J].中医杂志,2012,53(16)：1404-1406.
26. 陈玉琨,蒋梅.肺癌的中医治疗[J].新中医,1999,31(5)：31.
27.周建伟,朱斌,石建国,等.扶正固本结合辨证论治对非小细胞肺癌化疗的疗效分析[J].中国临床医学,2005,12(6)：1159.
28.陶炼,张悦红.辨证分型治疗非小细胞肺癌术后49例临床小结[J].湖南中医杂志,1999,15(3)：10.
29.刘嘉湘,施志明,李和根,等.益肺抗瘤饮治疗271例非小细胞肺癌临床观察[J].上海中医药杂志,2001(2)：4-6.
30.张明萍,王建军,李志宏,等.中晚期非小细胞肺癌中医证型的临床观察[J].世界中西医结合杂志,2012,7(8)：706-708.
31.王少墨,董志毅,屠洪斌,等.388例原发性肺癌中医证候分布状况分析[J].上海中医药大学学报,2013,27(5)：30-34.
32.谢长生,王东建,潘磊,等.561例肺癌中医证型与TNM分期及病理类型的相关性探索[J].浙江中医杂志,2010,45(6)：398-399.
33.顾梦飚.480例原发性肺癌中医证型与国际TNM分期相关性分析[J].上海中医杂志,1994,10(1)：1-3.
34.黄东华,周俊琴,鲁琴,等.140例中晚期肺癌患者中医证型分布规律研究[J].新中医,2013,45(6)：105-106.
35.黄立中,邹彩亮,何欣,等.非小细胞肺癌术后Ⅲ、Ⅳ期患者的中医证候分布规律初探[J]. 第三届国际中医、中西医结合肿瘤学术交流大会暨第十二届全国中西医结合肿瘤学术大会论文汇编,2010,721-726.
36.施志明.原发性肺癌中医辨证分型与西医分期及细胞类型关系.中国癌症杂志,1999,15(8)：317.
37.富琦,王笑民,杨国旺,等.肺癌患者化疗期间中医证型及升血汤干预作用研究[J].中国中医药信息杂志,2006,13(9)：17-18.
38.黎敬波,李科威,张征.非小细胞肺癌化疗前后证候变化的临床研究[J].新中医,2009,41(1)：18-20.
39.沈自尹,微观辨证和辨证微观化,中医杂志,1986, (2)； 55-57.
40.金孝信.微观辨证研究进展[J].临床荟萃,1993,8(22)：1044-1046.
41. 陈志强,吕立国.整体辨证、局部辨证与微观辨证-对现代中医辨证论治体系的思考[J].中国中西医结合杂志,2006,26(12)：1126-1127.
42. 张积仁.氩氦刀冷冻消融治疗肿瘤[J].中国肿瘤,2007,16(5)：335-337.
43.张积仁,主编.氩氦靶向肿瘤治疗技术.香港Pioneer Bioscience epublishing Co,2003,109-119.
44. 王洪武.肿瘤靶向治疗技术进展[J].中华医学信息导报,2003,18(7)：17.
45. Gazzaniga S, Bravo A, Goldszmid S, et al. Inflammary changes after cryosurgery induced necrosis in humanmelanoma xenografted in nude mice[J]. Invest Dermatol,2001,116(5):664-671.
46.李宝平周云芝尹晓明等.肺部肿瘤CT导向氢氦刀冷冻治疗前后的影像表现[J].中华放射学杂志,2007,41(7)：745-749.
47.王洪武,张燕群,罗晶,等.CT引导下经皮穿刺氢氦靶向治疗肺癌的临床应用[J].中华结核和呼吸杂志,2004,27(5)：311-314.
48.冯华松,段蕴铀,聂舟山,等.氩氦靶向治疗肺部肿瘤725例临床研究[J].中国肿瘤,2007,16(11)：906-909.
49.牛立志,何卫兵,贺轶松,等.氩氦刀冷冻治疗肺癌816例临床分析[J].中国(第七届)肿瘤微创治疗学术大会,2011,9：339-241.
50.安永辉,李秀莉,李娜,等.经皮穿刺氢氦刀靶向冷冻治疗非小细胞肺癌疗效观察[J].山东医药,2013,53(40)：47-48.
51.陈晔,董建堂,侯旭荣.氢氦刀联合放化疗治疗局部晚期非小细胞肺癌.中国疗养医学,2007,16(7)：391-393.
52.刘吉福,赵京,徐波,等.氩氦刀联合恩度治疗局部晚期肺癌疗效分析[J].现代肿瘤医学,2010,18(6)：1145-1146.
53.陈书昌,冯笑山,陈建民,等.氩氦刀冷冻消融联合放、化疗治疗NSCLC疗效观察.河南科技大学学报(医学版),2008,26(2)：105-107.
54.聂舟山,冯华松,张新红,等.氩氦刀联合靶向药物治疗晚期非小细胞肺癌临床研究[J].中国肿瘤,2011,20(1)：68-70.
55.曹肠,赵丹.氩氦刀联合GP(吉西他滨+顺铂)方案治疗非小细胞肺癌临床研究[J].中国医学工程,2013,21(10)：80-81.
56.张华玲,刘斯润,童涛,等.CT评价单纯氨氦刀冷冻术联合放疗粒子治疗非小细胞肺癌的疗效[J].中国介入影像学与治疗学,2012,9(7)：503-507.
57.王洪武,马洪明,罗凌飞,等.氩氦刀联合放/化疗粒子植入治疗肺癌[J].中国肺癌杂志,2009,12(5)：408-411.
58.蒋明.氩氦刀联合TP方案治疗老年非小细胞肺癌的临床观察[J].中国老年学杂志,2011,12(31)：4557-4559.
59.裴志东,倪明立.氩氦刀冷冻消融联合支气管动脉灌注化疗治疗Ⅲ～Ⅳ期非小细胞肺癌的临床疗效[J].肿瘤防治研究,2012,39(8)：1020-1022.
60. 曾繁开,谢艳群,杨莉瑕,等.氩氦刀冷冻消融治疗肺癌的临床体会[J].中国肿瘤外科杂志,2013,5(2)：133-136.
61.杜显峰,韩宝石,李天志.氩氦刀治疗中晚期非小细胞肺癌的Meta分析[J].军医进修学院学报,2010,31(7)：714-717.
62.韩克舜,杨亚琴,李文虎.肺癌中医辨证分型概述[J].中医临床研究,2013,5(16)：120-122.
63.孙宏新,蒋士卿,朴炳奎,等.益肺清化膏对早期非小细胞肺癌术后患者治 疗作用的随机对照研究[J].光明中医,2005,20(5)：55-58.
64.潘国凤,宋巧玲,吴良村,等.新加沙参麦冬汤联合放疗治疗中晚期非小细胞肺癌30例临床疗效观察[J].中华中医药杂,2010,25(6)：951-954.
65.纪钧,蔡忠仁,陈大可,等.金米益肺汤配合化疗治疗非小细胞肺癌及对生活质量的影响[J].陕西中医,2010,31(4)：387-388.
66.尤建良.晚期肺癌靶向治疗时中医药的切入[J].辽宁中医杂志,2006,33(10)：1227-1229.
67.胡凯文,姜敏,李占东,等.氩氦刀冷冻联合中药治疗肺癌65例的临床观察[J].中华中医药杂志,2005,20(5)： 295-297.
68.张恩欣.益气除痰法结合射频消融对中晚期肺癌患者生存质量的影响[J].福建中医药,2009,40(5)69-72.
69.周河.晚期肺癌”带瘤生存”的中西医结合调治思路[J].新中医,2011,43(5)：1-3.
70.王树堂. “带瘤生存”为癌症治疗带来了新观念-周岱翰教授诠释中医肿瘤学[J].新中医,2009,41(7)：107-108.
71. De Marinis F, Pereira,J R, Fossella F, et al. Lung cancer symptom scale outcomes in relation to standard efficacy measures:an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer[J]. J Thorac Oncol,2008,3:30-36.
72.刘建刚,韦巍,张积仁.氩氦冷冻联合中药治疗肿瘤对机体细胞免疫功能的影响[J].现代中西医结合杂志,2013,22(22)：2411-2417.
73.姜敏,周琴,左明焕,等.中药联合氩氦刀冷冻治疗晚期肺癌68例临床分析[J].北京中医药大学学报(中医临床版)2013,20(4)：8-10.
74.冯华松,聂舟山,段蕴铀,等.氩氦刀冷冻消融联合化疗治疗晚期非小细胞肺癌253例[J].中国肿瘤,2007,16(11)：898-901.
75. Clarke DM, Baust JM, Van Buskirk RG, et al. Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer[J]. Cryobiology,2001. 42 (4):274-285.
76.Clarke DM, Hollister WR, Baust JG. Crvosurgical Modeling. Sequence of Freezing and Cytotoxic Agent Application Affects Cell Death[J]. Mol Urol,1999,3(1):25-31.
77. Baust JG, Gage AA, Clarke D, et al. Cryosurgery-a putative approach to molecular-based optimization [J]. Cryobiology,2004,48(2):190-204.
78. 白广德,练组平,侯恩存,等.自拟扶正抑癌方配合氩氦刀化疗治疗中晚期非小细胞肺癌30例疗效观察[J].云南中医中药杂志,2008,29(2)：15-18.
79.孔繁宏,秦立东.氩氦刀靶向冷冻联合全身化疗治疗中晚期非小细胞肺癌的临床研究[J]. 中华肿瘤防治杂志,2011,18(14)：1125-1130.
80.曹阳,李泉旺,刘传波,等.氩氦刀联合中药治疗中晚期肺癌77例临床观察[J].中国中医药现代远程教育,2008,8(6)：925-926.
81. JIN Wei-qi,GUO Hong, SU Xue-gang, et al. Thermal imaging systemand medical thermal diagnostic technology. Infrared Technology,1999,9(5):6-12.
82.朱钧恺.对“脾体阴而用阳,胃体阳而用阴”的不同看法[J].江苏中医杂志,1982,2：47.
83.汪曙才.五脏皆体阴而用阳[J].江西中医杂志,1988,3：55-56.
84.胡凯文,卫月.癌症的中医诠释及相关病名辨析[J]. 中华中医药杂志(原中国医药学报),2011,26(1)：16-18.
1. Van der Bruggen P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science.1991,254:1643.
2. Kung P, Goldstein Q, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens[J]. Science. 1979,206(4416):347-349.
3. Hughes DA, Haslam PL, Townsend PJ, Turner-Warwick M. Numerical and functional alterations in circulatory lymphocytes in cigarette smokers[J]. Clin ExpImmunol.1985,61 (2):459-466.
4. Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90.
5. 郑荣寿,张思维,吴良有,等.中国肿瘤登记地区2008年恶性肿瘤发病和死亡分析[J].中国肿瘤,2012,21(1)：1-12.
6. Gianluigi Mazzoccoli, Maria Balzanelli, Antonio de Cata, et al Lymphocyte subpopulation anomalies in lung cancer patients and relationship to the stage of disease, in vivo,1999.13:205-210
7. Crystal L. Mackall. T-cell Immunodeficiency following cytotoxic antineoplastic therapy:a review. Stem Cell,2000.10-18
8. 刘莉,姚军霞,丁乾,等.非小细胞肺癌外周血CD4+CD25high调节T细胞分析[J].中国肿瘤临床,2006,33(10)：552-558.
9. Frances A, Shepherd, Jean-Yves Douillard, George R. Blumenschein张玲翻译.非小细胞肺癌的免疫治疗：改善患者预后的新方法[J].中国肺癌杂志,2013,16(4)：c9-c20.
10.汤钊猷主编.现代肿瘤学(第三版),上海：复旦大学出版社,2011,7,87-124.
11. Stsnojevic-Bakic N, Vuckovic-Dekic L, Radomirovic S, et al. Influence of surgery and anesthesia on lymphocyte functions in breast cancer patients:invitro effects of indomethacin. Neoplasms,1999,46(1):54-60.
12. Sanda Tuyaerts, Sonja Van Meirvenne, Aude Bonehill, et al. Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+regulatory T cells[J]. Leukocyte Biology,2007,82:1-13.
13. Gridelli C, Rossi A, Maione P, et al. Vaccines for the treatment of non-small cell lung cancer:a renewed anti-cancer strategy. Oncologist 2009;14:909-920.
14. Schuurhuis DH, Loan-Facsinay A, Nagelkerken B, et al. A antigen-antibody immune complexes empower dendritec efficiently prime specific CD8+CTL responses in vivo[J]. J Immunlo,2002,168(5):2240-2246.
15. Holliday GM, Le S。 Transforming growth factor-be reproduced by progress or tumor inhibits while II-be produced by reg or tumor enhances Langerhans cell migration from skin[J]. In Immune.2001,12(9):1147-1154.
16. Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+regulatory T cell proliferation[J]. J Exp Med,2005,202(7):19-29.
17.陈慰峰.医学免疫学.北京：人民卫生出版社,2000,65-74.
18. Coffman RL, MosmannTR. CD4+T-cell subsets:regulation of differentiation and function. Res Immunol,1991,142:7-9.
19. Mara Gerloni, Maurizio Zanetti. CD4 T cells in tumor immunity. Springer Semin Immun,2005,27:37-48.
20.牛德红.辅助性T细胞与肺癌免疫.国外医学肿瘤学分册,Jan2005,32(1)：56-58
21. Mara Gerloni, Maurizio Zanetti. CD4 T cells in tumor immunity. Springer Semin Immun,2005,27:37-48.
22. Drake CG, Ja ee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81.
23. Gallimore A, Godkin A. Regulatory T cells and tumour immunity observations in mice and men. Immunology,2008;123:157-163.
24. Cruz-Merino L, Grande-Pulido E,Albero-Tamarit A, et al. Cancer and immune response:old and new evidence for future challenges. Oncologist,2008,13:1246-1254.
25. Xu L, Xu W, Jiang Z, et al. Depletion of CD4+CD25high regulatory T cells form tumor infiltrationg lymphocytes predominantly induces Thl type immune response in vivo which inhibits tumor growth in adoptive immunotherapy. Cancer Biol Ther,2009,8:66-72.
26. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol,2004,34:336
27. John R, Handy Jr, James W, et al. Does video-assisted thoracoscopic lobectomy for lung cancer provide improved functional outcomes compared with open lobectomy[J]. European Journal of Cardio-thoracic Surgery,2010,37(2):451-455.
28. Jun Wu, Lewis L. Lanier. Natural killer cells and cancer. Adv Cancer Res,2003.27-56.
29. Mark J. Smyth, Erika Cretney, Janice M. Kelly, Jennifer A Westwood , et al. Activation of NK cell cytotoxicity. Molecular Immunology, 2005,42:501-510.
30. Gianluigi Mazzoccoli, Maria Balzanelli, Antonio de Cata, et al Lymphocyte subpopulation anomalies in lung cancer patients and relationship to the stage of disease. in vivo,1999.13:205-210
31.陆文洁,李泽坚.非小细胞肺癌患者外周血T细胞免疫与免疫增强治疗.中国协和医科大学博士学位论文,2006.5.
32. Chadwick D, Pidolopez J, Pires A, et al. A pilot study of the safety and efficacy of thymosin alphal augmenting immunereconstitution in HIV2 infected patients with low CD4+T count staking highly active antiret roviral therapy[J] Clin Exp Immunol,2003,134(3):477.
33. Crystal L. Mackall. T-cell Immunodeficiency following cytotoxic antineoplastic therapy:a review. Stem Cell,2000.10-18
34.郑康,王晋芬.肺癌患者围手术期免疫功能变化的研究,山西医科大学硕士学位论文,2010.5.
35. Haruhiko Nakamura, Hisashi Saji, Akihiko Ogata, Makoto Hosaka, et al. Immunologic parameters as a significant prognosyic factor in lung cancer. Lung Cancer,2002,37:161-9.
36.陈复兴,刘军权,周忠海等.癌症患者T细胞亚群的临床意义.细胞与分子免疫学杂志,2002,16(5)：55.
37. Oannides CG. Whiteside TL. T cell recognition of human tumors: Implirations for molecular immunotherapy of cancer, Clin Immunol and Immunopathol, 1993; 66:91.
38. Morton BA, Ramey WC, Paderon H et al. Monoclonal antibody defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer, Cancer Res.1986:46.
39. Gianluigi Mazzoccoli, Maria Balzanelli, Antonio de Cata, et al Lymphocyte subpopulation anomalies in lung cancer patients and relationship to the stage of disease. in vivo,1999.13:205-210
40. Khalil R Y, Khalil M M. Flow eytemetric study of T cell subsets in lymphocytic lieural effusions[J]. Cytometry,1997,30(4):204.
41. Wesselius IJ, Wheaton DL, Sherard SL, et al. Lymphocyte subsets in lung cancer[J]. Chest,1987,91(5):725-729
42.金从国,王熙才,伍治平,等.癌症患者外周血T细胞亚群水平及临床意义[J].肿瘤研究与临床,2003,15(1)：33-34
43. Haruhiko Nakamura, Hisashi Saji, Akihiko Ogata, Makoto Hosaka, et al Immunologic parameters as a significant prognosyic factor in lung cancer. Lung Cancer,2002,37:161-9.
44.叶伟成,董惠芳,周荣耀等.T细胞亚群等指标在药物治疗原发性肺癌的疗效评价和预后判断中的应用.上海医学检验杂志,2003,18(3)：1
45. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic e ect of epithelial and stromal lymphocyte in ltration in non-small cell lung cancer. Clin Cancer Res 2008:14:5220-5227.
46. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic e ect of epithelial and stromal lymphocyte in Itration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220-5227.
47. Zhuang X, Xia X, Wang C, et al. A high number of CD8+T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol 2010:18:24-28.
48. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent in Infiltration by CD8+T cells and CD4+T cells is a favourable prognostic factor in non-small cell lung carcinoma. Br J Cancer 2006:94:275-280.
49.陆文洁,李泽坚.非小细胞肺癌患者外周血T细胞免疫与免疫增强治疗.中国协和医科大学博士学位论文,2006,5.
50. Kiecolt-Glaser JK, Page GG, Marucha PT, et al. Psychological influences on surgical recovery。 Perspectives from pschoneuroimmunology. [J] Am Psychol.1998, 53(11):1209-1218.
51.蒲振业.完全胸腔镜与开放肺叶切除手术对非小细胞肺癌患者围手术期免疫功能及肿瘤预后影响的研究.南京医科大学硕士学位论文,2011.3.
52. Wright P, Smith A, Booth L, et al. Psychosocial difficuities, deprivation and cancer. Three questionnaire studies in volving 609 cancer patients[J]. Br J Cancer, 2005,93 (6):622-626.
53.张广丽.肺癌患者术前焦虑对T淋巴细胞亚群的影响及护理干预.放射免疫学杂志,2011,24(4)：475.
54. Cavallini G, Berti G, Tioli P. Leukocyte adherence inhibition assay in immunological basis of colon cancers. [J] Ital J Surg Sci.1984;14(4):281-8.
55. Nelson CJ, Lysle D. Severity, time and beta'adenergic rcceptor involvement in surgery-induced immune alterations[J]. J Surg Res,1998,80(2):115-122.
56. Ng CS, Wan S, Hui CW, Wan IY, Lee TW, Underwood MJ, et al Video-assisted thoracic surgery lobectomy for lung cancer is associated with less immunochemokine disturbances than thorac otomy. [J] Eur J Cardiothorac Surg. 2007:31(1):83-7.
57.宿杰.肺癌患者手术治疗前后 的细胞免疫功能指标变化[J].中国误诊学杂志,2008,8(11)：2587-2588.
58. Pollcok RE, Lotzova E, Stanford SD, et al。 Effect of surgical stress on murine natural killer cell cytotoxicity. [J] J Immunol,1987,138(1):171-178.
59.吴建兵,洪瑞,方伟群.胸腔镜肺叶切除术对非小细胞肺癌患者术后免疫功能的影响[J].中国医学创新,2013,10(17)：11-12.
60.孔繁宏,秦立东.氩氦刀靶向冷冻联合全身化疗治疗中晚期非小细胞肺癌的临床研究[J]. 中华肿瘤防治杂志,2011,18(14)：1125-1130.
61.姜领,赵昕,王联霞.冷冻治疗肺癌对机体免疫系统影响的临床观察[J].医 学检验与临床,2006,17(1)：86-87.
62.张彩霞,程颖,马丽霞,等.氩氦刀治疗晚期非小细胞肺癌免疫增强作用的研究[J].肿瘤,2007,27(9)：741-743.
63. Gazzaniga S, Bravo A, Goldszmid S, et al. Inflammary changes after cryosurgery induced necrosis in humanmelanoma xenografted in nude mice[J]. Invest Dermatol,2001,116(5):664-671.
64.狄松波,陈清勇.非小细胞肺癌患者化疗前后细胞免疫功能的变化[J].实用医学杂志,2009,25(14)：2341-2342.
65.曹爱良,彭顺清,严权.康艾联合化疗对非小细胞肺癌的临床疗效及免疫功能的影响.中外医学研究,2013,11(22)：45-46.
66. 肖亚嫔.艾迪注射液配合化疗治疗老年晚期非小细胞肺癌的临床观察[J].临床肺科杂志,2006,11(3)：286-287.
67.黄智芬,刘俊波,黎汉忠,等.参芪泻白散配合化疗治疗老年非小细胞肺癌30例报告[J].贵阳中医学院学报,2009,31(6)：42-44.
68.陆新岸.生脉注射液联合化疗对晚期非小细胞肺癌生活质量及免疫功能的影响.陕西中医,2011,32(4)：389-392.
69.李明,陈泽涛.益气化瘀法配合化疗治疗晚期非小细胞肺癌的临床研究,山东中医药大学博士学位论文,2012,4.
70.杨万毅,陈绪元.胸腺五肽配合化疗治疗中晚期肺癌患者的免疫状况观察[J].重庆医学,2010,39(4)：2054-2056.
71.赵增虎,丁瑞亮,宁宇,等.参一胶囊对小细胞肺癌患者化疗后免疫功能的影响.中国中医急诊,2010,19(4)：598-599.
72.郑惠如,金美玲,任涛,等.非小细胞肺癌患者化疗前后免疫功能的改变[J].复旦学报(医学版),2009,36(6)：696-700.
73.周清华,张力,王燕.临床肿瘤高级教程[M].北京：人民军医出版社,2011,375-437.
74.殷蔚伯,余子豪,徐国镇主编.肿瘤放射治疗学[M].北京：中国协和医科大学出社,第四版,2008：12.
75.崔玉芳.T和B淋巴细胞的辐射敏感性[J].国外军事医学放射医学分册.1984,1：19-23.
76. Ederichsen AC, Hjelmborg JB, Christensen PB, et al. Prognostic value of the CD4+/CD8+ratio of the tumor infiltrating lymphocytes in colorectal cancer and HLA-DR expression tumor cells. Cancer Immunol Immunother,2003,52(7):423-428.
77. Anderson RE. Ionizing radiation and the immune response[J], Adv Immunol, 1976,24(1):215-235.
78. Savina NP. Disordered thymus function and endocrine control as one ofthebases for the development of a late postradiation immunodeficiency [J],Radiat Biol Radioecol,1995,35(4):463-480.
79.黎福祥,陈龙,董永英,等.低剂量y射线全身照射对猴免疫功能的影响[J].中华放射医学与防护杂志,2004,24(4)：330-332.
80.李新莉,朱圣陶,徐文彦,等.放射治疗对肿瘤患者免疫功能的影响[J].苏州大学学报(医学版),2003,23(2)：190-192.
81.黎文亮,胡文华.人与狗外周血淋巴细胞放射敏感性的比较,军事医学科学院院刊,1986,10(1),11-14.
82.郑辉,涂序珉,甄荣,等.不同剂量辐射损伤后T淋巴细胞亚群,TH1和TH2变化观察[J].中国辐射卫生,2009,18(1)：13-15.
83.涂序珉,郑辉,甄荣,等.不同剂量辐射损伤后T淋巴细胞亚群及TH1和TH2的变化[J].癌变畸变突变,2012,24(6)：411-417.
84.吴大鹏,贾宗岭,蒋会娟,等.放射损伤对小鼠外周血T淋巴细胞亚群的影响[J].河南大学学报(医学版),2011,30(2)：108-109.
85. 曲爱忠,李岩.外周血C04+CD25+调节性T细胞与肿瘤相关性的研究.山东大学硕士学位论文,2009,5.
86.崔玉芳,丁彦青,徐菡,等.大剂量C线照射对小鼠免疫功能近期、远期的影响[J].细胞与分子免疫学杂志,2004.20(6)：675-677.
87.李国苗,李文辉.宣威肺腺癌患者放疗前后免疫功能的变化.昆明医科大学硕士学位论文,2013,5.
88.彭效祥,穆向魁,赵美红,等.质子放疗前后恶性肿瘤患者T细胞亚群的变化[J].医学检验与临床,2008,19(2)：16-18.
89.郭占文,李玉,拱玉华.非小细胞肺癌患者放疗前后机体免疫功能变化的研究[J]. 中国免疫学杂志,2000,16：103-105.
90.王春英,程明,汪德文.艾迪注射液联合放疗治疗非小细胞肺癌的临床观察[J]中国医药指南,2012,10(35)：130-131.
91.章继民,赵瑛.养阴解毒法对肺癌患者放疗后免疫功能干预的临床研究.江西中医药,2009,40(321)：31-32.
92.张霆.解毒疏络法对肺癌放疗免疫功能影响的临床研究[J]. 辽宁中医杂志,2009,36(1)：83-85.
93.袁颖,张洪珍.非小细胞肺癌患者外周血T淋巴细胞亚群和Treg的检测及临床意义.河北医科大学硕士学位论文,2013,3.
94.陈卓,于卫江.注射用黄芪多糖对非小细胞肺癌放疗的作用及对机体免疫的影响[J].中国实验方剂学杂志,2013,19(6)：309-313.
95. Rosenzweig KE, Sim SE, Mychalczak B, et al. Electivenodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy[J]. Int J radiat Oncol Biol Phys,2001,50(3):681-685.
96.周际昌.实用肿瘤内科学[M].2版.北京：人民卫生出版 社 ,1999：542,543,187,613
97. Jin F P, Zhang M. Progress of experimental researcheson Chinese herbal compounds for inducing tumor cellapoptosis[J]. Chin J Inteqr Med,2010,6:565.
98. Spiro S G, Tanner N T, Silvestri G A, et al. Lung cancer:Progress in diagnosis, staging and therapy[J]. Respirology,2010,15(1):44.
99.吴继,徐振晔,王中奇.中药肺岩宁方治疗晚期非小细胞肺癌疗效观察一对血清CEA、CYFR,A21-1及免疫功能的影响.辽宁中医杂志,2008,35(11)：1707-1708.
100. 顾丽梅,王国庆,徐新才,等.穴位敷贴对非小细胞肺癌患者免疫功能影响研究[J]. 实用中医药杂志,2010,26(8)：531.
101. 陈方帆.芪薏助康颗粒对非小细胞肺癌患者化疗期的免疫功能影响观察[J]. 浙江中医药大学学报,2006,30(4)：361-362.
102. 杨丽,徐非莉.晚期非小细胞肺癌患者免疫功能与中医证型的相关性研究,新疆医学2011,41：73-76.
103. 白广德,练组平,侯恩存,等.自拟扶正抑癌方配合氩氦刀化疗治疗中晚期非小细胞肺癌30例疗效观察[J].云南中医中药杂志,2008,29(2)：15-18.
104. 杜敏,史明.化疗联合鸦胆子油乳注射液治疗晚期非小细胞肺癌疗效观察[J].肿瘤基础与临床,2006,19(2)：151-152.
105. 胡守友,李明慧,孙世顷,等.鸦胆子油皂化物治疗肿瘤的实验研究[J].南京中医药大学学报,2007,23(4)：244-246.
106. 莫绍雄.鸦胆子油乳联合化疗对非小细胞肺癌术后患者 免疫功能的影响[J]. 现代中西医结合杂志,2010,19(9)：1098-1099.
107. 阎丽珠.扶正祛邪汤配合化疗对中晚期非小细胞肺癌患者生存质量及机体免疫功能的影响.河北中医,2009,31(12)：1836-1837.
108. 章继民,赵瑛.养阴解毒法对肺癌患者放疗后免疫功能干预的临床研究江西中医药,2009,40(321)：31-32.
109. 周雍明,朴炳奎,侯炜,等.肺瘤平膏改善非小细胞肺癌患者免疫状态及预后的临床观察[J]. 中国中医药信息杂志,2008,15(5)：78-79.
110. Su W, Xu Z Y. Gene polymorphism and physical constitution theory:Starting point of exploring syndromes of lung cancer[J]. Chin J Inteqr Med,2010,1:15.
111.于明薇,孙桂芝,吴洁,等.黄芪、苏木及其组方对荷瘤小鼠脾调节性T细胞表达及血清细胞因子水平的干预作用[J].北京中医药大学学报,2010,4：241.
1.赫捷,陈万青.2012中国肿瘤登记年报[M].北京：军事医学科学出版社,2012,10.
2.孙桂芝主编.实用中医肿瘤学[M].北京：中国中医药出版社,2010：151.
3. Waun Ki Hong, MD:Anne S. Tsao, MD. Lung Carcinoma. The Merck Manual for Health Care Professionals, Merck & Co. Inc. http://www.merckmanuals.com/2012.4.22.
4.朱明章,吴万根.中医专方联合化疗治疗非小细胞肺癌疗效及组方研究.广州中医药大学博士学位论文,2013,5.
5. Guessous I.Guessous I.Cornuz J, Paccaud F, Lung cancer screening:current situation and perspective, Swiss Med Wkly,2007 Jun 2;137(21-22):304-11.
6. Clarke DM, Baust JM, Van Buskirk RG, et al. Chemo-cryo combination therapy:an adjunct ive model for the treatment of prostate cancer [J]. Cryobiology,2001,42 (4):274-285.
7. Clarke DM, Hollister WR, Baust JG. Cryosurgical Modeling. Sequence of Freezing and Cytotoxic Agent Application Affects Cell Death[J]. Mol Urol,1999,3(1):25-31.
8.姜领,赵昕,王联霞.冷冻治疗肺癌对机体免疫系统影响的临床观察[J].医学检验与临床,2006,17(1)：86-87.
9. Gazzaniga S, Bravo A, Goldszmid S, et al. Inf lammary changes after cryosurgery induced necrosis in humanmelanoma xenografted in nude mice[J]. Invest Dermatol,2001,116(5):664-671.
10.关念波,刘浩,林洪生.肺癌中医药治疗的研究进展及展望[J].临床肿瘤学杂志,2013,18(3):264-267.
11.韩克舜,杨亚琴,李文虎.肺癌中医辨证分型概述[J].中医临床研究,2013,5(16)：120-122.
12.《原发性肺癌诊疗规范(2011年版)》.中华人民共和国国家卫生和计划生育委员会,2011.2.12.
13.Goldstraw P, Crowley J, Chansky K, et al. The 1ASLC Lung Cancer StagingProject: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. J Thorac Onco12007; 2:706-714
14. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual,7th ed. New York: Springer.2010.
15.张积仁主编.氩氦靶向肿瘤治疗技术. Pioneer Bioscience Publishing Co.2003,1-3,38.
16. Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting:Integrating Immunity's Roles in Cancer Suppression and Promotion. Science.2011,331(6024):1565-1570.
17.中国抗癌协会肺癌专业委员会.2010中国肺癌临床指南[S].北京：人民卫生出版社,2010：1
18.孙燕,石远凯.临床肿瘤内科手册[M].北京：人民卫生出版社,2008：388-389。
19.王妙新,娄冬华.消癌平注射液治疗晚期非小细胞肺癌的Meta分析[J].分子诊断与治疗杂志2014,6(1)：57-61.
20.沈洪,倪菲菲.β-榄香烯抗肿瘤免疫效应的研究进展[J].江苏医药,2013,39(11)：1287-1291.
21.杨晓玲.康莱特注射液对晚期恶性肿瘤患者生活质量及免疫功能影响的临床观察[J].临山西中医,2013,29(11)：20-21.
22.王婉茹,洪滨,李康.华蟾素注射液辅助治疗晚期NSCLC的疗效评估[J].临床肺科杂志,2013,18(2)：203-204.
23.周河.晚期肺癌”带瘤生存”的中西医结合调治思路[J].新中医,2011,43(5)：1-3.
24.王树堂.”带瘤生存”为癌症治疗带来了新观念-周岱翰教授诠释中医肿瘤学[J].新中 医,2009,41 (7):107-108.
25.Gazzaniga S, Bravo A, Goldszmid S, et al. Inf lammary changes after cryosurgerv induced necrosis in humanmelanoma xenografted in nude mice[J]. Invest Dermatol,2001,116(5):664-671.
26.涂铭珊,田菲.温针灸对肺癌患者免疫功能的影响[J].四川中医药,2013,31(8)：151-152.
27.胡凯文,姜敏,李占东,等.氩氦刀冷冻联合中药治疗肺癌65例的临床观察[J].中华中医药杂志,2005,20(5)：295-297.
28.姜敏,周琴,左明焕,等.中药联合氩氦刀冷冻治疗晚期肺癌68例临床分析[J].北京中医药大学学报(中医临床版)2013,20(4)：8-10.
29.曹阳,李泉旺,刘传波,等.氩氦刀联合中药治疗中晚期肺癌77例临床观察[J].中国中医药现代远程教育,2008,8(6)：925-926.
30.金孝信.微观辨证研究进展[J].临床荟萃,1993,8(22)：1044-1046.
31.陈志强,吕立国.整体辨证、局部辨证与微观辨证-对现代中医辨证论治体系的思考[J].中国中西医结合杂志,2006,26(12)：1126-1127.
32. JIN Wei-qi,GUO Hong, SU Xue-gang, et al. Thermal imaging systemand medical thermal diagnostic technology. Infrared Technology,1999,9(5):6-12.
33.朱钧恺.对“脾体阴而用阳,胃体阳而用阴”的不同看法[J].江苏中医杂志,1982,2：47.
34.汪曙才.五脏皆体阴而用阳[J].江西中医杂志,1988,3：55-56.
35.胡凯文,卫月.癌症的中医诠释及相关病名辨析[J].中华中医药杂志(原中国医药学报),2011,26(1)：16-18.
36. Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors:Revised RESCIST guideline (Versionl.1)[J]. Eur J Cancer,2009:228.
37. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteriain solid tumours:revised RECIST guideline (version 1.1). Eur J Cancer,2009,45(2):228-247.
38.Lencioni R. Llovet JM. Modified RECIST(mRECIST) assessment for hepato-cellular carcinoma. Semin Liver Dis,2010,30(1):52-60.
39.Edeline J, BoucherE, Rolland Y, et al. Comparison of tumor response by response Evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated Withsorafenih for hepatoeellular carcinoma[J]. Cancer,2012,118:147-156.
40.不可手术切除的肝细胞癌的疗效评价标准—改良RECIST标准更可靠[J].介入放射学杂志,2012,21(3)：177-179.
41.杜显峰,韩宝石,李天志.氩氦刀治疗中晚期非小细胞肺癌的Meta分析[J].军医进修学院学报,2010,31(7)：714-717.
42.De Marinis F, Pereira,J R, Fossella F, et al.Lung cancer symptom scale outcomes in relation to standard efficacy measures:an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer[J]. J Thorac Oncol,2008,3:30-36.
43.肖越勇,吴斌,张肖,等.CT引导下经皮穿刺适形冷冻消融治疗肺癌的临床分析[J]中华放射学杂志,2010,44(2)：185-189.
44. Oannides CG. Whiteside TL. T cell recognition of human tumors.-Implirations for molecular immunotherapy of cancer,Clin Immunol and Immunopathol,1993;66:91.
45. Gianluigi Mazzoccoli, Maria Balzanelli, Antonio de Cata, et al. Lymphocyte subpopulation anomalies in lung cancer patients and relationship to the stage of disease, in vivo,1999.13:205-210.
46. Khalil R Y, Khalil M M. Flow eytemetric study of T cell subsets in lymphocytic lieural effusions[J]. Cytometry,1997,30(4):204.
47.姜领,赵昕,王联霞.冷冻治疗肺癌对机体免疫系统影响的临床观察[J].医学检验与临床,2006,17(1)：86-87.48.张彩霞,程颖,马丽霞,等.氩氦刀治疗晚期非小细胞肺癌免疫增强作用的研究[J].肿 瘤,2007,27(9)：741-743.
49.孔繁宏,秦立东.氩氦刀靶向冷冻联合全身化疗治疗中晚期非小细胞肺癌的临床研究[J].中华肿瘤防治杂志,2011,18(14)：1125-1130.
50.狄松波,陈清勇.非小细胞肺癌患者化疗前后细胞免疫功能的变化[J].实用医学杂志,2009,25(14)：2341-2342.
51.曹爱良,彭顺清,严权.康艾联合化疗对非小细胞肺癌的临床疗效及免疫功能的影响.中外医学研究,2013,11(22)：45-46.
52.赵增虎,丁瑞亮,宁宇,等.参一胶囊对小细胞肺癌患者化疗后免疫功能的影响.中国中医急诊,2010,19(4)：598-599.
53.殷蔚伯,余子豪,徐国镇主编.肿瘤放射治疗学[M].北京：中国协和医科大学出社,第四版,2008：12.
54.涂序珉,郑辉,甄荣,等.不同剂量辐射损伤后T淋巴细胞亚群及TH1和TH2的变化[J].癌变畸变突变,2012,24(6)：411-417.
55.陈卓,于卫江.注射用黄芪多糖对非小细胞肺癌放疗的作用及对机体免疫的影响[J].中国实验方剂学杂志,2013,19(6)：309-313.
56. Jin F P, Zhang M. Progress of experimental researcheson Chinese herbal compounds for inducing tumor cell apoptosis[J]. Chin J Inteqr Med,2010,6:565.
2. 赫捷,陈万青.2012中国肿瘤登记年报[M].北京：军事医学科学出版社,2012,10.
3. 孙桂芝主编.实用中医肿瘤学[M].北京：中国中医药出版社,2010：151.
4. Waun Ki Hong, MD:Anne S. Tsao, MD. Lung Carcinoma. The Merck Manual for Health Care Professionals, Merck & Co. Inc. http://www.merckmanuals.com/2012.4.22.
5. 朱明章,吴万根.中医专方联合化疗治疗非小细胞肺癌疗效及组方研究.广州中医药大学博士学位论文,2013,5.
7. 赵炜.李佩文治疗肺癌的经验[J].北京中医,2002,21(6)：329.
8. 郁仁存.中医肿瘤学(上册).北京：北京科学出版社,1983,275.
9. 周岱翰.肿瘤治验集要[M].广州：广东省教育出版社,1997.36.
10.刘嘉湘.肺癌证治.中医杂志,1986,(3)：4-7.
11.周晓园,陶凯.顾振东治疗肿瘤的经验[J].中医杂志,1999,40(7)：395.
12.魏华.晚期肺癌的中医药治疗.湖北中医杂志,2000,2(：8)12-13.
13.姜敏,胡凯文.肺癌患者氩氦刀冷冻术后中医证候特点研究.北京中医药大学七年制学位论文,2004.5.
14.朴炳奎.原发性支气管肺癌中西医结合治疗方案[J].中国肿瘤,1995,4(5)：4-6.
15.刘嘉湘,施志明,徐振晔,等.滋阴生津益气温阳法治疗晚期原发性肺腺癌的临床观察[J].中医杂志,1995,36(3)：155-158.
16.孙建立.刘嘉湘教授治疗原发性非小细胞肺癌辨证和用药规律分析[J],第三届国际中医、中西医结合肿瘤学术交流大会暨第十二届全国中西医结合肿瘤学术大会论文汇编[C].2010,230-235.
17.王笑民,郁仁存.晚期非小细胞肺癌患者气虚血瘀证的研究.中国中西医结合杂志,1994,14：(12)：724.
18.李忠,陈信义,姜苗.肿癌中医临床研究进展与用药思路[J].中国医药学报,2004,19(3)：176.
19.郑翠娥.顾振东治疗肺癌经验[J].山东中医杂志,1996,15(5)：225-226.
20.左明焕,王芬,孙韬.晚期肺癌的中医证候研究[J].北京中医药大学学报,2003,10(4)：7-9.
21.侯丽,姜苗,陈信义,等.晚期非小细胞肺癌中医证候特征回顾性临床研究田.中国中医药信息杂志,2007,14(4)：19-21.
22.张月,张培彤,赵冰,等.基于聚类分析的肺癌中医证候分类及诊断的研究[J].北京中医药人学学报,2009,32(2)：132-135.
23.王芬,周而复,陈文强,等.中晚期肺癌中医证候与患者生活质量关系的分析[J].中国中医药信息杂志,2007,14(2)：21-22.
24. 陈涛,陈茂华.原发性支气管肺癌临床证型的文献统计分析[J].时珍国医国药,2006,17(5)：854-855.
25.游捷,李泰峰.303例老年原发性支气管肺癌中医证候分型[J].中医杂志,2012,53(16)：1404-1406.
26. 陈玉琨,蒋梅.肺癌的中医治疗[J].新中医,1999,31(5)：31.
27.周建伟,朱斌,石建国,等.扶正固本结合辨证论治对非小细胞肺癌化疗的疗效分析[J].中国临床医学,2005,12(6)：1159.
28.陶炼,张悦红.辨证分型治疗非小细胞肺癌术后49例临床小结[J].湖南中医杂志,1999,15(3)：10.
29.刘嘉湘,施志明,李和根,等.益肺抗瘤饮治疗271例非小细胞肺癌临床观察[J].上海中医药杂志,2001(2)：4-6.
30.张明萍,王建军,李志宏,等.中晚期非小细胞肺癌中医证型的临床观察[J].世界中西医结合杂志,2012,7(8)：706-708.
31.王少墨,董志毅,屠洪斌,等.388例原发性肺癌中医证候分布状况分析[J].上海中医药大学学报,2013,27(5)：30-34.
32.谢长生,王东建,潘磊,等.561例肺癌中医证型与TNM分期及病理类型的相关性探索[J].浙江中医杂志,2010,45(6)：398-399.
33.顾梦飚.480例原发性肺癌中医证型与国际TNM分期相关性分析[J].上海中医杂志,1994,10(1)：1-3.
34.黄东华,周俊琴,鲁琴,等.140例中晚期肺癌患者中医证型分布规律研究[J].新中医,2013,45(6)：105-106.
35.黄立中,邹彩亮,何欣,等.非小细胞肺癌术后Ⅲ、Ⅳ期患者的中医证候分布规律初探[J]. 第三届国际中医、中西医结合肿瘤学术交流大会暨第十二届全国中西医结合肿瘤学术大会论文汇编,2010,721-726.
36.施志明.原发性肺癌中医辨证分型与西医分期及细胞类型关系.中国癌症杂志,1999,15(8)：317.
37.富琦,王笑民,杨国旺,等.肺癌患者化疗期间中医证型及升血汤干预作用研究[J].中国中医药信息杂志,2006,13(9)：17-18.
38.黎敬波,李科威,张征.非小细胞肺癌化疗前后证候变化的临床研究[J].新中医,2009,41(1)：18-20.
39.沈自尹,微观辨证和辨证微观化,中医杂志,1986, (2)； 55-57.
40.金孝信.微观辨证研究进展[J].临床荟萃,1993,8(22)：1044-1046.
41. 陈志强,吕立国.整体辨证、局部辨证与微观辨证-对现代中医辨证论治体系的思考[J].中国中西医结合杂志,2006,26(12)：1126-1127.
42. 张积仁.氩氦刀冷冻消融治疗肿瘤[J].中国肿瘤,2007,16(5)：335-337.
43.张积仁,主编.氩氦靶向肿瘤治疗技术.香港Pioneer Bioscience epublishing Co,2003,109-119.
44. 王洪武.肿瘤靶向治疗技术进展[J].中华医学信息导报,2003,18(7)：17.
45. Gazzaniga S, Bravo A, Goldszmid S, et al. Inflammary changes after cryosurgery induced necrosis in humanmelanoma xenografted in nude mice[J]. Invest Dermatol,2001,116(5):664-671.
46.李宝平周云芝尹晓明等.肺部肿瘤CT导向氢氦刀冷冻治疗前后的影像表现[J].中华放射学杂志,2007,41(7)：745-749.
47.王洪武,张燕群,罗晶,等.CT引导下经皮穿刺氢氦靶向治疗肺癌的临床应用[J].中华结核和呼吸杂志,2004,27(5)：311-314.
48.冯华松,段蕴铀,聂舟山,等.氩氦靶向治疗肺部肿瘤725例临床研究[J].中国肿瘤,2007,16(11)：906-909.
49.牛立志,何卫兵,贺轶松,等.氩氦刀冷冻治疗肺癌816例临床分析[J].中国(第七届)肿瘤微创治疗学术大会,2011,9：339-241.
50.安永辉,李秀莉,李娜,等.经皮穿刺氢氦刀靶向冷冻治疗非小细胞肺癌疗效观察[J].山东医药,2013,53(40)：47-48.
51.陈晔,董建堂,侯旭荣.氢氦刀联合放化疗治疗局部晚期非小细胞肺癌.中国疗养医学,2007,16(7)：391-393.
52.刘吉福,赵京,徐波,等.氩氦刀联合恩度治疗局部晚期肺癌疗效分析[J].现代肿瘤医学,2010,18(6)：1145-1146.
53.陈书昌,冯笑山,陈建民,等.氩氦刀冷冻消融联合放、化疗治疗NSCLC疗效观察.河南科技大学学报(医学版),2008,26(2)：105-107.
54.聂舟山,冯华松,张新红,等.氩氦刀联合靶向药物治疗晚期非小细胞肺癌临床研究[J].中国肿瘤,2011,20(1)：68-70.
55.曹肠,赵丹.氩氦刀联合GP(吉西他滨+顺铂)方案治疗非小细胞肺癌临床研究[J].中国医学工程,2013,21(10)：80-81.
56.张华玲,刘斯润,童涛,等.CT评价单纯氨氦刀冷冻术联合放疗粒子治疗非小细胞肺癌的疗效[J].中国介入影像学与治疗学,2012,9(7)：503-507.
57.王洪武,马洪明,罗凌飞,等.氩氦刀联合放/化疗粒子植入治疗肺癌[J].中国肺癌杂志,2009,12(5)：408-411.
58.蒋明.氩氦刀联合TP方案治疗老年非小细胞肺癌的临床观察[J].中国老年学杂志,2011,12(31)：4557-4559.
59.裴志东,倪明立.氩氦刀冷冻消融联合支气管动脉灌注化疗治疗Ⅲ～Ⅳ期非小细胞肺癌的临床疗效[J].肿瘤防治研究,2012,39(8)：1020-1022.
60. 曾繁开,谢艳群,杨莉瑕,等.氩氦刀冷冻消融治疗肺癌的临床体会[J].中国肿瘤外科杂志,2013,5(2)：133-136.
61.杜显峰,韩宝石,李天志.氩氦刀治疗中晚期非小细胞肺癌的Meta分析[J].军医进修学院学报,2010,31(7)：714-717.
62.韩克舜,杨亚琴,李文虎.肺癌中医辨证分型概述[J].中医临床研究,2013,5(16)：120-122.
63.孙宏新,蒋士卿,朴炳奎,等.益肺清化膏对早期非小细胞肺癌术后患者治 疗作用的随机对照研究[J].光明中医,2005,20(5)：55-58.
64.潘国凤,宋巧玲,吴良村,等.新加沙参麦冬汤联合放疗治疗中晚期非小细胞肺癌30例临床疗效观察[J].中华中医药杂,2010,25(6)：951-954.
65.纪钧,蔡忠仁,陈大可,等.金米益肺汤配合化疗治疗非小细胞肺癌及对生活质量的影响[J].陕西中医,2010,31(4)：387-388.
66.尤建良.晚期肺癌靶向治疗时中医药的切入[J].辽宁中医杂志,2006,33(10)：1227-1229.
67.胡凯文,姜敏,李占东,等.氩氦刀冷冻联合中药治疗肺癌65例的临床观察[J].中华中医药杂志,2005,20(5)： 295-297.
68.张恩欣.益气除痰法结合射频消融对中晚期肺癌患者生存质量的影响[J].福建中医药,2009,40(5)69-72.
69.周河.晚期肺癌”带瘤生存”的中西医结合调治思路[J].新中医,2011,43(5)：1-3.
70.王树堂. “带瘤生存”为癌症治疗带来了新观念-周岱翰教授诠释中医肿瘤学[J].新中医,2009,41(7)：107-108.
71. De Marinis F, Pereira,J R, Fossella F, et al. Lung cancer symptom scale outcomes in relation to standard efficacy measures:an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer[J]. J Thorac Oncol,2008,3:30-36.
72.刘建刚,韦巍,张积仁.氩氦冷冻联合中药治疗肿瘤对机体细胞免疫功能的影响[J].现代中西医结合杂志,2013,22(22)：2411-2417.
73.姜敏,周琴,左明焕,等.中药联合氩氦刀冷冻治疗晚期肺癌68例临床分析[J].北京中医药大学学报(中医临床版)2013,20(4)：8-10.
74.冯华松,聂舟山,段蕴铀,等.氩氦刀冷冻消融联合化疗治疗晚期非小细胞肺癌253例[J].中国肿瘤,2007,16(11)：898-901.
75. Clarke DM, Baust JM, Van Buskirk RG, et al. Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer[J]. Cryobiology,2001. 42 (4):274-285.
76.Clarke DM, Hollister WR, Baust JG. Crvosurgical Modeling. Sequence of Freezing and Cytotoxic Agent Application Affects Cell Death[J]. Mol Urol,1999,3(1):25-31.
77. Baust JG, Gage AA, Clarke D, et al. Cryosurgery-a putative approach to molecular-based optimization [J]. Cryobiology,2004,48(2):190-204.
78. 白广德,练组平,侯恩存,等.自拟扶正抑癌方配合氩氦刀化疗治疗中晚期非小细胞肺癌30例疗效观察[J].云南中医中药杂志,2008,29(2)：15-18.
79.孔繁宏,秦立东.氩氦刀靶向冷冻联合全身化疗治疗中晚期非小细胞肺癌的临床研究[J]. 中华肿瘤防治杂志,2011,18(14)：1125-1130.
80.曹阳,李泉旺,刘传波,等.氩氦刀联合中药治疗中晚期肺癌77例临床观察[J].中国中医药现代远程教育,2008,8(6)：925-926.
81. JIN Wei-qi,GUO Hong, SU Xue-gang, et al. Thermal imaging systemand medical thermal diagnostic technology. Infrared Technology,1999,9(5):6-12.
82.朱钧恺.对“脾体阴而用阳,胃体阳而用阴”的不同看法[J].江苏中医杂志,1982,2：47.
83.汪曙才.五脏皆体阴而用阳[J].江西中医杂志,1988,3：55-56.
84.胡凯文,卫月.癌症的中医诠释及相关病名辨析[J]. 中华中医药杂志(原中国医药学报),2011,26(1)：16-18.
1. Van der Bruggen P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science.1991,254:1643.
2. Kung P, Goldstein Q, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens[J]. Science. 1979,206(4416):347-349.
3. Hughes DA, Haslam PL, Townsend PJ, Turner-Warwick M. Numerical and functional alterations in circulatory lymphocytes in cigarette smokers[J]. Clin ExpImmunol.1985,61 (2):459-466.
4. Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90.
5. 郑荣寿,张思维,吴良有,等.中国肿瘤登记地区2008年恶性肿瘤发病和死亡分析[J].中国肿瘤,2012,21(1)：1-12.
6. Gianluigi Mazzoccoli, Maria Balzanelli, Antonio de Cata, et al Lymphocyte subpopulation anomalies in lung cancer patients and relationship to the stage of disease, in vivo,1999.13:205-210
7. Crystal L. Mackall. T-cell Immunodeficiency following cytotoxic antineoplastic therapy:a review. Stem Cell,2000.10-18
8. 刘莉,姚军霞,丁乾,等.非小细胞肺癌外周血CD4+CD25high调节T细胞分析[J].中国肿瘤临床,2006,33(10)：552-558.
9. Frances A, Shepherd, Jean-Yves Douillard, George R. Blumenschein张玲翻译.非小细胞肺癌的免疫治疗：改善患者预后的新方法[J].中国肺癌杂志,2013,16(4)：c9-c20.
10.汤钊猷主编.现代肿瘤学(第三版),上海：复旦大学出版社,2011,7,87-124.
11. Stsnojevic-Bakic N, Vuckovic-Dekic L, Radomirovic S, et al. Influence of surgery and anesthesia on lymphocyte functions in breast cancer patients:invitro effects of indomethacin. Neoplasms,1999,46(1):54-60.
12. Sanda Tuyaerts, Sonja Van Meirvenne, Aude Bonehill, et al. Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+regulatory T cells[J]. Leukocyte Biology,2007,82:1-13.
13. Gridelli C, Rossi A, Maione P, et al. Vaccines for the treatment of non-small cell lung cancer:a renewed anti-cancer strategy. Oncologist 2009;14:909-920.
14. Schuurhuis DH, Loan-Facsinay A, Nagelkerken B, et al. A antigen-antibody immune complexes empower dendritec efficiently prime specific CD8+CTL responses in vivo[J]. J Immunlo,2002,168(5):2240-2246.
15. Holliday GM, Le S。 Transforming growth factor-be reproduced by progress or tumor inhibits while II-be produced by reg or tumor enhances Langerhans cell migration from skin[J]. In Immune.2001,12(9):1147-1154.
16. Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+regulatory T cell proliferation[J]. J Exp Med,2005,202(7):19-29.
17.陈慰峰.医学免疫学.北京：人民卫生出版社,2000,65-74.
18. Coffman RL, MosmannTR. CD4+T-cell subsets:regulation of differentiation and function. Res Immunol,1991,142:7-9.
19. Mara Gerloni, Maurizio Zanetti. CD4 T cells in tumor immunity. Springer Semin Immun,2005,27:37-48.
20.牛德红.辅助性T细胞与肺癌免疫.国外医学肿瘤学分册,Jan2005,32(1)：56-58
21. Mara Gerloni, Maurizio Zanetti. CD4 T cells in tumor immunity. Springer Semin Immun,2005,27:37-48.
22. Drake CG, Ja ee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81.
23. Gallimore A, Godkin A. Regulatory T cells and tumour immunity observations in mice and men. Immunology,2008;123:157-163.
24. Cruz-Merino L, Grande-Pulido E,Albero-Tamarit A, et al. Cancer and immune response:old and new evidence for future challenges. Oncologist,2008,13:1246-1254.
25. Xu L, Xu W, Jiang Z, et al. Depletion of CD4+CD25high regulatory T cells form tumor infiltrationg lymphocytes predominantly induces Thl type immune response in vivo which inhibits tumor growth in adoptive immunotherapy. Cancer Biol Ther,2009,8:66-72.
26. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol,2004,34:336
27. John R, Handy Jr, James W, et al. Does video-assisted thoracoscopic lobectomy for lung cancer provide improved functional outcomes compared with open lobectomy[J]. European Journal of Cardio-thoracic Surgery,2010,37(2):451-455.
28. Jun Wu, Lewis L. Lanier. Natural killer cells and cancer. Adv Cancer Res,2003.27-56.
29. Mark J. Smyth, Erika Cretney, Janice M. Kelly, Jennifer A Westwood , et al. Activation of NK cell cytotoxicity. Molecular Immunology, 2005,42:501-510.
30. Gianluigi Mazzoccoli, Maria Balzanelli, Antonio de Cata, et al Lymphocyte subpopulation anomalies in lung cancer patients and relationship to the stage of disease. in vivo,1999.13:205-210
31.陆文洁,李泽坚.非小细胞肺癌患者外周血T细胞免疫与免疫增强治疗.中国协和医科大学博士学位论文,2006.5.
32. Chadwick D, Pidolopez J, Pires A, et al. A pilot study of the safety and efficacy of thymosin alphal augmenting immunereconstitution in HIV2 infected patients with low CD4+T count staking highly active antiret roviral therapy[J] Clin Exp Immunol,2003,134(3):477.
33. Crystal L. Mackall. T-cell Immunodeficiency following cytotoxic antineoplastic therapy:a review. Stem Cell,2000.10-18
34.郑康,王晋芬.肺癌患者围手术期免疫功能变化的研究,山西医科大学硕士学位论文,2010.5.
35. Haruhiko Nakamura, Hisashi Saji, Akihiko Ogata, Makoto Hosaka, et al. Immunologic parameters as a significant prognosyic factor in lung cancer. Lung Cancer,2002,37:161-9.
36.陈复兴,刘军权,周忠海等.癌症患者T细胞亚群的临床意义.细胞与分子免疫学杂志,2002,16(5)：55.
37. Oannides CG. Whiteside TL. T cell recognition of human tumors: Implirations for molecular immunotherapy of cancer, Clin Immunol and Immunopathol, 1993; 66:91.
38. Morton BA, Ramey WC, Paderon H et al. Monoclonal antibody defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer, Cancer Res.1986:46.
39. Gianluigi Mazzoccoli, Maria Balzanelli, Antonio de Cata, et al Lymphocyte subpopulation anomalies in lung cancer patients and relationship to the stage of disease. in vivo,1999.13:205-210
40. Khalil R Y, Khalil M M. Flow eytemetric study of T cell subsets in lymphocytic lieural effusions[J]. Cytometry,1997,30(4):204.
41. Wesselius IJ, Wheaton DL, Sherard SL, et al. Lymphocyte subsets in lung cancer[J]. Chest,1987,91(5):725-729
42.金从国,王熙才,伍治平,等.癌症患者外周血T细胞亚群水平及临床意义[J].肿瘤研究与临床,2003,15(1)：33-34
43. Haruhiko Nakamura, Hisashi Saji, Akihiko Ogata, Makoto Hosaka, et al Immunologic parameters as a significant prognosyic factor in lung cancer. Lung Cancer,2002,37:161-9.
44.叶伟成,董惠芳,周荣耀等.T细胞亚群等指标在药物治疗原发性肺癌的疗效评价和预后判断中的应用.上海医学检验杂志,2003,18(3)：1
45. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic e ect of epithelial and stromal lymphocyte in ltration in non-small cell lung cancer. Clin Cancer Res 2008:14:5220-5227.
46. Al-Shibli KI, Donnem T, Al-Saad S, et al. Prognostic e ect of epithelial and stromal lymphocyte in Itration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220-5227.
47. Zhuang X, Xia X, Wang C, et al. A high number of CD8+T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol 2010:18:24-28.
48. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent in Infiltration by CD8+T cells and CD4+T cells is a favourable prognostic factor in non-small cell lung carcinoma. Br J Cancer 2006:94:275-280.
49.陆文洁,李泽坚.非小细胞肺癌患者外周血T细胞免疫与免疫增强治疗.中国协和医科大学博士学位论文,2006,5.
50. Kiecolt-Glaser JK, Page GG, Marucha PT, et al. Psychological influences on surgical recovery。 Perspectives from pschoneuroimmunology. [J] Am Psychol.1998, 53(11):1209-1218.
51.蒲振业.完全胸腔镜与开放肺叶切除手术对非小细胞肺癌患者围手术期免疫功能及肿瘤预后影响的研究.南京医科大学硕士学位论文,2011.3.
52. Wright P, Smith A, Booth L, et al. Psychosocial difficuities, deprivation and cancer. Three questionnaire studies in volving 609 cancer patients[J]. Br J Cancer, 2005,93 (6):622-626.
53.张广丽.肺癌患者术前焦虑对T淋巴细胞亚群的影响及护理干预.放射免疫学杂志,2011,24(4)：475.
54. Cavallini G, Berti G, Tioli P. Leukocyte adherence inhibition assay in immunological basis of colon cancers. [J] Ital J Surg Sci.1984;14(4):281-8.
55. Nelson CJ, Lysle D. Severity, time and beta'adenergic rcceptor involvement in surgery-induced immune alterations[J]. J Surg Res,1998,80(2):115-122.
56. Ng CS, Wan S, Hui CW, Wan IY, Lee TW, Underwood MJ, et al Video-assisted thoracic surgery lobectomy for lung cancer is associated with less immunochemokine disturbances than thorac otomy. [J] Eur J Cardiothorac Surg. 2007:31(1):83-7.
57.宿杰.肺癌患者手术治疗前后 的细胞免疫功能指标变化[J].中国误诊学杂志,2008,8(11)：2587-2588.
58. Pollcok RE, Lotzova E, Stanford SD, et al。 Effect of surgical stress on murine natural killer cell cytotoxicity. [J] J Immunol,1987,138(1):171-178.
59.吴建兵,洪瑞,方伟群.胸腔镜肺叶切除术对非小细胞肺癌患者术后免疫功能的影响[J].中国医学创新,2013,10(17)：11-12.
60.孔繁宏,秦立东.氩氦刀靶向冷冻联合全身化疗治疗中晚期非小细胞肺癌的临床研究[J]. 中华肿瘤防治杂志,2011,18(14)：1125-1130.
61.姜领,赵昕,王联霞.冷冻治疗肺癌对机体免疫系统影响的临床观察[J].医 学检验与临床,2006,17(1)：86-87.
62.张彩霞,程颖,马丽霞,等.氩氦刀治疗晚期非小细胞肺癌免疫增强作用的研究[J].肿瘤,2007,27(9)：741-743.
63. Gazzaniga S, Bravo A, Goldszmid S, et al. Inflammary changes after cryosurgery induced necrosis in humanmelanoma xenografted in nude mice[J]. Invest Dermatol,2001,116(5):664-671.
64.狄松波,陈清勇.非小细胞肺癌患者化疗前后细胞免疫功能的变化[J].实用医学杂志,2009,25(14)：2341-2342.
65.曹爱良,彭顺清,严权.康艾联合化疗对非小细胞肺癌的临床疗效及免疫功能的影响.中外医学研究,2013,11(22)：45-46.
66. 肖亚嫔.艾迪注射液配合化疗治疗老年晚期非小细胞肺癌的临床观察[J].临床肺科杂志,2006,11(3)：286-287.
67.黄智芬,刘俊波,黎汉忠,等.参芪泻白散配合化疗治疗老年非小细胞肺癌30例报告[J].贵阳中医学院学报,2009,31(6)：42-44.
68.陆新岸.生脉注射液联合化疗对晚期非小细胞肺癌生活质量及免疫功能的影响.陕西中医,2011,32(4)：389-392.
69.李明,陈泽涛.益气化瘀法配合化疗治疗晚期非小细胞肺癌的临床研究,山东中医药大学博士学位论文,2012,4.
70.杨万毅,陈绪元.胸腺五肽配合化疗治疗中晚期肺癌患者的免疫状况观察[J].重庆医学,2010,39(4)：2054-2056.
71.赵增虎,丁瑞亮,宁宇,等.参一胶囊对小细胞肺癌患者化疗后免疫功能的影响.中国中医急诊,2010,19(4)：598-599.
72.郑惠如,金美玲,任涛,等.非小细胞肺癌患者化疗前后免疫功能的改变[J].复旦学报(医学版),2009,36(6)：696-700.
73.周清华,张力,王燕.临床肿瘤高级教程[M].北京：人民军医出版社,2011,375-437.
74.殷蔚伯,余子豪,徐国镇主编.肿瘤放射治疗学[M].北京：中国协和医科大学出社,第四版,2008：12.
75.崔玉芳.T和B淋巴细胞的辐射敏感性[J].国外军事医学放射医学分册.1984,1：19-23.
76. Ederichsen AC, Hjelmborg JB, Christensen PB, et al. Prognostic value of the CD4+/CD8+ratio of the tumor infiltrating lymphocytes in colorectal cancer and HLA-DR expression tumor cells. Cancer Immunol Immunother,2003,52(7):423-428.
77. Anderson RE. Ionizing radiation and the immune response[J], Adv Immunol, 1976,24(1):215-235.
78. Savina NP. Disordered thymus function and endocrine control as one ofthebases for the development of a late postradiation immunodeficiency [J],Radiat Biol Radioecol,1995,35(4):463-480.
79.黎福祥,陈龙,董永英,等.低剂量y射线全身照射对猴免疫功能的影响[J].中华放射医学与防护杂志,2004,24(4)：330-332.
80.李新莉,朱圣陶,徐文彦,等.放射治疗对肿瘤患者免疫功能的影响[J].苏州大学学报(医学版),2003,23(2)：190-192.
81.黎文亮,胡文华.人与狗外周血淋巴细胞放射敏感性的比较,军事医学科学院院刊,1986,10(1),11-14.
82.郑辉,涂序珉,甄荣,等.不同剂量辐射损伤后T淋巴细胞亚群,TH1和TH2变化观察[J].中国辐射卫生,2009,18(1)：13-15.
83.涂序珉,郑辉,甄荣,等.不同剂量辐射损伤后T淋巴细胞亚群及TH1和TH2的变化[J].癌变畸变突变,2012,24(6)：411-417.
84.吴大鹏,贾宗岭,蒋会娟,等.放射损伤对小鼠外周血T淋巴细胞亚群的影响[J].河南大学学报(医学版),2011,30(2)：108-109.
85. 曲爱忠,李岩.外周血C04+CD25+调节性T细胞与肿瘤相关性的研究.山东大学硕士学位论文,2009,5.
86.崔玉芳,丁彦青,徐菡,等.大剂量C线照射对小鼠免疫功能近期、远期的影响[J].细胞与分子免疫学杂志,2004.20(6)：675-677.
87.李国苗,李文辉.宣威肺腺癌患者放疗前后免疫功能的变化.昆明医科大学硕士学位论文,2013,5.
88.彭效祥,穆向魁,赵美红,等.质子放疗前后恶性肿瘤患者T细胞亚群的变化[J].医学检验与临床,2008,19(2)：16-18.
89.郭占文,李玉,拱玉华.非小细胞肺癌患者放疗前后机体免疫功能变化的研究[J]. 中国免疫学杂志,2000,16：103-105.
90.王春英,程明,汪德文.艾迪注射液联合放疗治疗非小细胞肺癌的临床观察[J]中国医药指南,2012,10(35)：130-131.
91.章继民,赵瑛.养阴解毒法对肺癌患者放疗后免疫功能干预的临床研究.江西中医药,2009,40(321)：31-32.
92.张霆.解毒疏络法对肺癌放疗免疫功能影响的临床研究[J]. 辽宁中医杂志,2009,36(1)：83-85.
93.袁颖,张洪珍.非小细胞肺癌患者外周血T淋巴细胞亚群和Treg的检测及临床意义.河北医科大学硕士学位论文,2013,3.
94.陈卓,于卫江.注射用黄芪多糖对非小细胞肺癌放疗的作用及对机体免疫的影响[J].中国实验方剂学杂志,2013,19(6)：309-313.
95. Rosenzweig KE, Sim SE, Mychalczak B, et al. Electivenodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy[J]. Int J radiat Oncol Biol Phys,2001,50(3):681-685.
96.周际昌.实用肿瘤内科学[M].2版.北京：人民卫生出版 社 ,1999：542,543,187,613
97. Jin F P, Zhang M. Progress of experimental researcheson Chinese herbal compounds for inducing tumor cellapoptosis[J]. Chin J Inteqr Med,2010,6:565.
98. Spiro S G, Tanner N T, Silvestri G A, et al. Lung cancer:Progress in diagnosis, staging and therapy[J]. Respirology,2010,15(1):44.
99.吴继,徐振晔,王中奇.中药肺岩宁方治疗晚期非小细胞肺癌疗效观察一对血清CEA、CYFR,A21-1及免疫功能的影响.辽宁中医杂志,2008,35(11)：1707-1708.
100. 顾丽梅,王国庆,徐新才,等.穴位敷贴对非小细胞肺癌患者免疫功能影响研究[J]. 实用中医药杂志,2010,26(8)：531.
101. 陈方帆.芪薏助康颗粒对非小细胞肺癌患者化疗期的免疫功能影响观察[J]. 浙江中医药大学学报,2006,30(4)：361-362.
102. 杨丽,徐非莉.晚期非小细胞肺癌患者免疫功能与中医证型的相关性研究,新疆医学2011,41：73-76.
103. 白广德,练组平,侯恩存,等.自拟扶正抑癌方配合氩氦刀化疗治疗中晚期非小细胞肺癌30例疗效观察[J].云南中医中药杂志,2008,29(2)：15-18.
104. 杜敏,史明.化疗联合鸦胆子油乳注射液治疗晚期非小细胞肺癌疗效观察[J].肿瘤基础与临床,2006,19(2)：151-152.
105. 胡守友,李明慧,孙世顷,等.鸦胆子油皂化物治疗肿瘤的实验研究[J].南京中医药大学学报,2007,23(4)：244-246.
106. 莫绍雄.鸦胆子油乳联合化疗对非小细胞肺癌术后患者 免疫功能的影响[J]. 现代中西医结合杂志,2010,19(9)：1098-1099.
107. 阎丽珠.扶正祛邪汤配合化疗对中晚期非小细胞肺癌患者生存质量及机体免疫功能的影响.河北中医,2009,31(12)：1836-1837.
108. 章继民,赵瑛.养阴解毒法对肺癌患者放疗后免疫功能干预的临床研究江西中医药,2009,40(321)：31-32.
109. 周雍明,朴炳奎,侯炜,等.肺瘤平膏改善非小细胞肺癌患者免疫状态及预后的临床观察[J]. 中国中医药信息杂志,2008,15(5)：78-79.
110. Su W, Xu Z Y. Gene polymorphism and physical constitution theory:Starting point of exploring syndromes of lung cancer[J]. Chin J Inteqr Med,2010,1:15.
111.于明薇,孙桂芝,吴洁,等.黄芪、苏木及其组方对荷瘤小鼠脾调节性T细胞表达及血清细胞因子水平的干预作用[J].北京中医药大学学报,2010,4：241.
1.赫捷,陈万青.2012中国肿瘤登记年报[M].北京：军事医学科学出版社,2012,10.
2.孙桂芝主编.实用中医肿瘤学[M].北京：中国中医药出版社,2010：151.
3. Waun Ki Hong, MD:Anne S. Tsao, MD. Lung Carcinoma. The Merck Manual for Health Care Professionals, Merck & Co. Inc. http://www.merckmanuals.com/2012.4.22.
4.朱明章,吴万根.中医专方联合化疗治疗非小细胞肺癌疗效及组方研究.广州中医药大学博士学位论文,2013,5.
5. Guessous I.Guessous I.Cornuz J, Paccaud F, Lung cancer screening:current situation and perspective, Swiss Med Wkly,2007 Jun 2;137(21-22):304-11.
6. Clarke DM, Baust JM, Van Buskirk RG, et al. Chemo-cryo combination therapy:an adjunct ive model for the treatment of prostate cancer [J]. Cryobiology,2001,42 (4):274-285.
7. Clarke DM, Hollister WR, Baust JG. Cryosurgical Modeling. Sequence of Freezing and Cytotoxic Agent Application Affects Cell Death[J]. Mol Urol,1999,3(1):25-31.
8.姜领,赵昕,王联霞.冷冻治疗肺癌对机体免疫系统影响的临床观察[J].医学检验与临床,2006,17(1)：86-87.
9. Gazzaniga S, Bravo A, Goldszmid S, et al. Inf lammary changes after cryosurgery induced necrosis in humanmelanoma xenografted in nude mice[J]. Invest Dermatol,2001,116(5):664-671.
10.关念波,刘浩,林洪生.肺癌中医药治疗的研究进展及展望[J].临床肿瘤学杂志,2013,18(3):264-267.
11.韩克舜,杨亚琴,李文虎.肺癌中医辨证分型概述[J].中医临床研究,2013,5(16)：120-122.
12.《原发性肺癌诊疗规范(2011年版)》.中华人民共和国国家卫生和计划生育委员会,2011.2.12.
13.Goldstraw P, Crowley J, Chansky K, et al. The 1ASLC Lung Cancer StagingProject: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. J Thorac Onco12007; 2:706-714
14. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual,7th ed. New York: Springer.2010.
15.张积仁主编.氩氦靶向肿瘤治疗技术. Pioneer Bioscience Publishing Co.2003,1-3,38.
16. Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting:Integrating Immunity's Roles in Cancer Suppression and Promotion. Science.2011,331(6024):1565-1570.
17.中国抗癌协会肺癌专业委员会.2010中国肺癌临床指南[S].北京：人民卫生出版社,2010：1
18.孙燕,石远凯.临床肿瘤内科手册[M].北京：人民卫生出版社,2008：388-389。
19.王妙新,娄冬华.消癌平注射液治疗晚期非小细胞肺癌的Meta分析[J].分子诊断与治疗杂志2014,6(1)：57-61.
20.沈洪,倪菲菲.β-榄香烯抗肿瘤免疫效应的研究进展[J].江苏医药,2013,39(11)：1287-1291.
21.杨晓玲.康莱特注射液对晚期恶性肿瘤患者生活质量及免疫功能影响的临床观察[J].临山西中医,2013,29(11)：20-21.
22.王婉茹,洪滨,李康.华蟾素注射液辅助治疗晚期NSCLC的疗效评估[J].临床肺科杂志,2013,18(2)：203-204.
23.周河.晚期肺癌”带瘤生存”的中西医结合调治思路[J].新中医,2011,43(5)：1-3.
24.王树堂.”带瘤生存”为癌症治疗带来了新观念-周岱翰教授诠释中医肿瘤学[J].新中 医,2009,41 (7):107-108.
25.Gazzaniga S, Bravo A, Goldszmid S, et al. Inf lammary changes after cryosurgerv induced necrosis in humanmelanoma xenografted in nude mice[J]. Invest Dermatol,2001,116(5):664-671.
26.涂铭珊,田菲.温针灸对肺癌患者免疫功能的影响[J].四川中医药,2013,31(8)：151-152.
27.胡凯文,姜敏,李占东,等.氩氦刀冷冻联合中药治疗肺癌65例的临床观察[J].中华中医药杂志,2005,20(5)：295-297.
28.姜敏,周琴,左明焕,等.中药联合氩氦刀冷冻治疗晚期肺癌68例临床分析[J].北京中医药大学学报(中医临床版)2013,20(4)：8-10.
29.曹阳,李泉旺,刘传波,等.氩氦刀联合中药治疗中晚期肺癌77例临床观察[J].中国中医药现代远程教育,2008,8(6)：925-926.
30.金孝信.微观辨证研究进展[J].临床荟萃,1993,8(22)：1044-1046.
31.陈志强,吕立国.整体辨证、局部辨证与微观辨证-对现代中医辨证论治体系的思考[J].中国中西医结合杂志,2006,26(12)：1126-1127.
32. JIN Wei-qi,GUO Hong, SU Xue-gang, et al. Thermal imaging systemand medical thermal diagnostic technology. Infrared Technology,1999,9(5):6-12.
33.朱钧恺.对“脾体阴而用阳,胃体阳而用阴”的不同看法[J].江苏中医杂志,1982,2：47.
34.汪曙才.五脏皆体阴而用阳[J].江西中医杂志,1988,3：55-56.
35.胡凯文,卫月.癌症的中医诠释及相关病名辨析[J].中华中医药杂志(原中国医药学报),2011,26(1)：16-18.
36. Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors:Revised RESCIST guideline (Versionl.1)[J]. Eur J Cancer,2009:228.
37. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteriain solid tumours:revised RECIST guideline (version 1.1). Eur J Cancer,2009,45(2):228-247.
38.Lencioni R. Llovet JM. Modified RECIST(mRECIST) assessment for hepato-cellular carcinoma. Semin Liver Dis,2010,30(1):52-60.
39.Edeline J, BoucherE, Rolland Y, et al. Comparison of tumor response by response Evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated Withsorafenih for hepatoeellular carcinoma[J]. Cancer,2012,118:147-156.
40.不可手术切除的肝细胞癌的疗效评价标准—改良RECIST标准更可靠[J].介入放射学杂志,2012,21(3)：177-179.
41.杜显峰,韩宝石,李天志.氩氦刀治疗中晚期非小细胞肺癌的Meta分析[J].军医进修学院学报,2010,31(7)：714-717.
42.De Marinis F, Pereira,J R, Fossella F, et al.Lung cancer symptom scale outcomes in relation to standard efficacy measures:an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer[J]. J Thorac Oncol,2008,3:30-36.
43.肖越勇,吴斌,张肖,等.CT引导下经皮穿刺适形冷冻消融治疗肺癌的临床分析[J]中华放射学杂志,2010,44(2)：185-189.
44. Oannides CG. Whiteside TL. T cell recognition of human tumors.-Implirations for molecular immunotherapy of cancer,Clin Immunol and Immunopathol,1993;66:91.
45. Gianluigi Mazzoccoli, Maria Balzanelli, Antonio de Cata, et al. Lymphocyte subpopulation anomalies in lung cancer patients and relationship to the stage of disease, in vivo,1999.13:205-210.
46. Khalil R Y, Khalil M M. Flow eytemetric study of T cell subsets in lymphocytic lieural effusions[J]. Cytometry,1997,30(4):204.
47.姜领,赵昕,王联霞.冷冻治疗肺癌对机体免疫系统影响的临床观察[J].医学检验与临床,2006,17(1)：86-87.48.张彩霞,程颖,马丽霞,等.氩氦刀治疗晚期非小细胞肺癌免疫增强作用的研究[J].肿 瘤,2007,27(9)：741-743.
49.孔繁宏,秦立东.氩氦刀靶向冷冻联合全身化疗治疗中晚期非小细胞肺癌的临床研究[J].中华肿瘤防治杂志,2011,18(14)：1125-1130.
50.狄松波,陈清勇.非小细胞肺癌患者化疗前后细胞免疫功能的变化[J].实用医学杂志,2009,25(14)：2341-2342.
51.曹爱良,彭顺清,严权.康艾联合化疗对非小细胞肺癌的临床疗效及免疫功能的影响.中外医学研究,2013,11(22)：45-46.
52.赵增虎,丁瑞亮,宁宇,等.参一胶囊对小细胞肺癌患者化疗后免疫功能的影响.中国中医急诊,2010,19(4)：598-599.
53.殷蔚伯,余子豪,徐国镇主编.肿瘤放射治疗学[M].北京：中国协和医科大学出社,第四版,2008：12.
54.涂序珉,郑辉,甄荣,等.不同剂量辐射损伤后T淋巴细胞亚群及TH1和TH2的变化[J].癌变畸变突变,2012,24(6)：411-417.
55.陈卓,于卫江.注射用黄芪多糖对非小细胞肺癌放疗的作用及对机体免疫的影响[J].中国实验方剂学杂志,2013,19(6)：309-313.
56. Jin F P, Zhang M. Progress of experimental researcheson Chinese herbal compounds for inducing tumor cell apoptosis[J]. Chin J Inteqr Med,2010,6:565.